Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
- AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for central nervous system disorders, including Alzheimer's disease (AD) dementia and tuberous sclerosis complex (TSC)-related epilepsy, today shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate AD.
- 03/25/2025
|
Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?
- Cassava Sciences (SAVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 03/07/2025
|
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
- AUSTIN, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, including Alzheimer's disease and tuberous sclerosis complex (TSC)-related seizures, today reported financial results for the year ended December 31, 2024 and provided a business update.
- 03/03/2025
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128597&wire=1 or contact Joseph E. Levi, Esq.
- 02/10/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128562&wire=1 or contact Joseph E. Levi, Esq.
- 02/10/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
- NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128534&wire=1 or contact Joseph E. Levi, Esq.
- 02/10/2025
|
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128502&wire=1 or contact Joseph E. Levi, Esq.
- 02/10/2025
|
SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 02/10/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVA
- NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
- 02/10/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128462&wire=1 or contact Joseph E. Levi, Esq.
- 02/10/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc.(SAVA) Shareholders
- NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128349&wire=1 or contact Joseph E. Levi, Esq.
- 02/10/2025
|
FINAL REMINDER SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Cassava Sciences, Inc. Investors to Participate in the Class Action Lawsuit
- NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 02/10/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 02/10/2025
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128314&wire=1 or contact Joseph E. Levi, Esq.
- 02/09/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128311&wire=1 or contact Joseph E. Levi, Esq.
- 02/09/2025
|
SAVA DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVA
- NEW YORK, Feb. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 02/09/2025
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128299&wire=1 or contact Joseph E. Levi, Esq.
- 02/09/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc.(SAVA) Shareholders
- NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128247&wire=1 or contact Joseph E. Levi, Esq.
- 02/09/2025
|
Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm
- RADNOR, Pa. , Feb. 9, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period").
- 02/09/2025
|
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128206&wire=1 or contact Joseph E. Levi, Esq.
- 02/09/2025
|
SAVA FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in Securities Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / February 9, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ:SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 02/09/2025
|
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK, NY / ACCESS Newswire / February 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 02/09/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128191&wire=1 or contact Joseph E. Levi, Esq.
- 02/09/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128171&wire=1 or contact Joseph E. Levi, Esq.
- 02/09/2025
|
FINAL SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava Sciences, Inc. Investors to Join the Class Action Lawsuit
- NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 02/09/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 8, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128100&wire=1 or contact Joseph E. Levi, Esq.
- 02/08/2025
|
SAVA FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in Securities Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / February 8, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ:SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 02/08/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 8, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128068&wire=1 or contact Joseph E. Levi, Esq.
- 02/08/2025
|
SAVA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action Lawsuit
- RADNOR, Pa., Feb. 08, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, 2025.
- 02/08/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit – SAVA
- NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
- 02/07/2025
|
SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
- NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024. Cassava describes itself as a “clinical stage biotechnology company, with a focus on developing drugs for neurodegenerative diseases.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-365.
- 02/07/2025
|
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127988&wire=1 or contact Joseph E. Levi, Esq.
- 02/07/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127956&wire=1 or contact Joseph E. Levi, Esq.
- 02/07/2025
|
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cassava To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Cassava between February 7, 2024 and November 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the February 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 02/07/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127926&wire=1 or contact Joseph E. Levi, Esq.
- 02/07/2025
|
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK, NY / ACCESS Newswire / February 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 02/07/2025
|
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 7, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127807&wire=1 or contact Joseph E. Levi, Esq.
- 02/07/2025
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 02/07/2025
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 02/07/2025
|
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127733&wire=1 or contact Joseph E. Levi, Esq.
- 02/06/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, LA / ACCESS Newswire / February 6, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NASDAQ:SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 02/06/2025
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127714&wire=1 or contact Joseph E. Levi, Esq.
- 02/06/2025
|
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Shareholders
- NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).
- 02/06/2025
|
Shareholders that lost money on Cassava Sciences, Inc. (SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127625&wire=1 or contact Joseph E. Levi, Esq.
- 02/06/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Shareholders
- NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127623&wire=1 or contact Joseph E. Levi, Esq.
- 02/06/2025
|
SAVA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVA
- NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 02/06/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127590&wire=1 or contact Joseph E. Levi, Esq.
- 02/06/2025
|
SAVA Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action Lawsuit
- RADNOR, PA / ACCESS Newswire / February 6, 2025 / The law firm of Kessler Topaz Meltzer & Check, LLP(www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava") (NASDAQ:SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period"). The lead plaintiff deadline is February 10, 2025.
- 02/06/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
- NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127506&wire=1 or contact Joseph E. Levi, Esq.
- 02/06/2025
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 02/06/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SAVA
- NEW YORK , Feb. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 02/06/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127460&wire=1 or contact Joseph E. Levi, Esq.
- 02/05/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.
- 02/05/2025
|
Shareholders that Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky about Pending Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127426&wire=1 or contact Joseph E. Levi, Esq.
- 02/05/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers.
- 02/05/2025
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127397&wire=1 or contact Joseph E. Levi, Esq.
- 02/05/2025
|
SAVA Deadline: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- NEW YORK , Feb. 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 02/05/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127343&wire=1 or contact Joseph E. Levi, Esq.
- 02/05/2025
|
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK CITY, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 02/05/2025
|
SAVA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / February 5, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ:SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 02/05/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127241&wire=1 or contact Joseph E. Levi, Esq.
- 02/05/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 02/05/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127200&wire=1 or contact Joseph E. Levi, Esq.
- 02/04/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.
- 02/04/2025
|
Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SAVA
- NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127153&wire=1 or contact Joseph E. Levi, Esq.
- 02/04/2025
|
Cassava Sciences, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. February 10, 2025 Deadline to file Lead Plaintiff Motion
- Investors can contact the law firm at no cost to learn more about recovering their losses
- 02/04/2025
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127128&wire=1 or contact Joseph E. Levi, Esq.
- 02/04/2025
|
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 02/04/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
- NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127096&wire=1 or contact Joseph E. Levi, Esq.
- 02/04/2025
|
Investors who lost money on Cassava Sciences, Inc. (SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127091&wire=1 or contact Joseph E. Levi, Esq.
- 02/04/2025
|
SAVA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / February 4, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ:SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 02/04/2025
|
Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127061&wire=1 or contact Joseph E. Levi, Esq.
- 02/04/2025
|
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 – SAVA
- NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
- 02/04/2025
|
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of February 10, 2025 Lead Plaintiff Deadline in Cassava Sciences, Inc. (SAVA) Class Action – Investors With Significant Losses Encouraged to Contact the Firm
- ATLANTA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA). The lawsuit alleges that Defendants created a false impression that they possessed reliable information pertaining to the Company's drug prospects and anticipated growth while also minimizing risk from a potential drug failure.
- 02/04/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127054&wire=1 or contact Joseph E. Levi, Esq.
- 02/04/2025
|
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cassava To Contact Him Directly To Discuss Their Options
- 02/04/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=127007&wire=1 or contact Joseph E. Levi, Esq.
- 02/04/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 02/04/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 02/04/2025
|
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126962&wire=1 or contact Joseph E. Levi, Esq.
- 02/03/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, LA / ACCESS Newswire / February 3, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM:SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 02/03/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126940&wire=1 or contact Joseph E. Levi, Esq.
- 02/03/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126876&wire=1 or contact Joseph E. Levi, Esq.
- 02/03/2025
|
SAVA DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVA
- NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 02/03/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126859&wire=1 or contact Joseph E. Levi, Esq.
- 02/03/2025
|
SAVA DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action - SAVA
- NEW YORK CITY, NY / ACCESS Newswire / February 3, 2025 / WHY: New York, N.Y., February 3, 2025.
- 02/03/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126710&wire=1 or contact Joseph E. Levi, Esq.
- 02/03/2025
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / February 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 02/03/2025
|
Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK , Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 02/03/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126657&wire=1 or contact Joseph E. Levi, Esq.
- 02/02/2025
|
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action SAVA
- NEW YORK, NY / ACCESS Newswire / February 2, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ:SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 02/02/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc.(SAVA) Shareholders
- NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126646&wire=1 or contact Joseph E. Levi, Esq.
- 02/02/2025
|
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126623&wire=1 or contact Joseph E. Levi, Esq.
- 02/02/2025
|
Kessler Topaz Meltzer & Check, LLP Reminds SAVA Shareholders of Deadline in Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. (SAVA)
- RADNOR, Pa., Feb. 02, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, 2025.
- 02/02/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126540&wire=1 or contact Joseph E. Levi, Esq.
- 02/02/2025
|
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cassava To Contact Him Directly To Discuss Their Options
- 02/02/2025
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126538&wire=1 or contact Joseph E. Levi, Esq.
- 02/02/2025
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 02/02/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESS Newswire / February 1, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126479&wire=1 or contact Joseph E. Levi, Esq.
- 02/01/2025
|
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVA
- NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Rosen Law Firm PA WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ:SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 02/01/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 02/01/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS , Jan. 31, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 01/31/2025
|
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
- NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126443&wire=1 or contact Joseph E. Levi, Esq.
- 01/31/2025
|
SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 01/31/2025
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126403&wire=1 or contact Joseph E. Levi, Esq.
- 01/31/2025
|
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVA
- NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 01/31/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
- NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126391&wire=1 or contact Joseph E. Levi, Esq.
- 01/31/2025
|
SAVA SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. (SAVA)
- RADNOR, Pa. , Jan. 31, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period").
- 01/31/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc. (SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126330&wire=1 or contact Joseph E. Levi, Esq.
- 01/31/2025
|
Faruqi & Faruqi Reminds Cassava Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cassava To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / If you purchased or acquired securities in Cassava between February 7, 2024 and November 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA) and reminds investors of the February 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 01/31/2025
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126237&wire=1 or contact Joseph E. Levi, Esq.
- 01/31/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/31/2025
|
Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 01/31/2025
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126203&wire=1 or contact Joseph E. Levi, Esq.
- 01/30/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, LA / ACCESS Newswire / January 30, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM:SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 01/30/2025
|
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126169&wire=1 or contact Joseph E. Levi, Esq.
- 01/30/2025
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126160&wire=1 or contact Joseph E. Levi, Esq.
- 01/30/2025
|
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVA
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ:SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 01/30/2025
|
Contact Levi & Korsinsky by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences, Inc.(SAVA)
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126141&wire=1 or contact Joseph E. Levi, Esq.
- 01/30/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers.
- 01/30/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc.(SAVA) Shareholders
- NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
- 01/30/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=126092&wire=1 or contact Joseph E. Levi, Esq.
- 01/30/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/30/2025
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125981&wire=1 or contact Joseph E. Levi, Esq.
- 01/30/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/30/2025
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact The Gross Law Firm
- NEW YORK , Jan. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/30/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - SAVA
- NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125955&wire=1 or contact Joseph E. Levi, Esq.
- 01/29/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.
- 01/29/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125874&wire=1 or contact Joseph E. Levi, Esq.
- 01/29/2025
|
The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 – SAVA
- NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).
- 01/29/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125850&wire=1 or contact Joseph E. Levi, Esq.
- 01/29/2025
|
ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / January 29, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ:SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 01/29/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
- NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125702&wire=1 or contact Joseph E. Levi, Esq.
- 01/29/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/29/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK CITY, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125684&wire=1 or contact Joseph E. Levi, Esq.
- 01/29/2025
|
Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.
- RADNOR, PA / ACCESS Newswire / January 29, 2025 / The law firm of Kessler Topaz Meltzer & Check, LLP(www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava") (NASDAQ:SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period"). The lead plaintiff deadline is February 10, 2025.
- 01/29/2025
|
Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 28, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125668&wire=1 or contact Joseph E. Levi, Esq.
- 01/28/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.
- 01/28/2025
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125648&wire=1 or contact Joseph E. Levi, Esq.
- 01/28/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Shareholders
- NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125617&wire=1 or contact Joseph E. Levi, Esq.
- 01/28/2025
|
Lost Money on Cassava Sciences, Inc. (SAVA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125583&wire=1 or contact Joseph E. Levi, Esq.
- 01/28/2025
|
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 01/28/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc. (SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125566&wire=1 or contact Joseph E. Levi, Esq.
- 01/28/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK CITY, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125557&wire=1 or contact Joseph E. Levi, Esq.
- 01/28/2025
|
SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 01/28/2025
|
ROSEN, LEADING INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / January 28, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ:SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 01/28/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/28/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/28/2025
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 01/28/2025
|
Shareholders that Lost Money on Cassava Sciences, Inc. (SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125473&wire=1 or contact Joseph E. Levi, Esq.
- 01/27/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, LA / ACCESS Newswire / January 27, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NASDAQ:SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 01/27/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125445&wire=1 or contact Joseph E. Levi, Esq.
- 01/27/2025
|
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / January 27, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ:SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 01/27/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125431&wire=1 or contact Joseph E. Levi, Esq.
- 01/27/2025
|
Lead Plaintiff Deadline Approaching in SAVA: Kessler Topaz Meltzer & Check, LLP Reminds Investors A Securities Fraud Class Action Has Been Filed Against Cassava Sciences, Inc. (SAVA)
- RADNOR, Pa., Jan. 27, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, 2025.
- 01/27/2025
|
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125380&wire=1 or contact Joseph E. Levi, Esq.
- 01/27/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit – SAVA
- NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
- 01/27/2025
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125360&wire=1 or contact Joseph E. Levi, Esq.
- 01/27/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125264&wire=1 or contact Joseph E. Levi, Esq.
- 01/27/2025
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/27/2025
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The Gross Law Firm
- NEW YORK , Jan. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/27/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / January 26, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125185&wire=1 or contact Joseph E. Levi, Esq.
- 01/26/2025
|
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / January 26, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 01/26/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/26/2025
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / January 26, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125101&wire=1 or contact Joseph E. Levi, Esq.
- 01/26/2025
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/26/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / January 25, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125093&wire=1 or contact Joseph E. Levi, Esq.
- 01/25/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESS Newswire / January 25, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125058&wire=1 or contact Joseph E. Levi, Esq.
- 01/25/2025
|
ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Jan. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 01/25/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS , Jan. 24, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Texas.
- 01/24/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125026&wire=1 or contact Joseph E. Levi, Esq.
- 01/24/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers.
- 01/24/2025
|
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=125014&wire=1 or contact Joseph E. Levi, Esq.
- 01/24/2025
|
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / January 24, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ:SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 01/24/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124986&wire=1 or contact Joseph E. Levi, Esq.
- 01/24/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA
- NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/24/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc. (SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124824&wire=1 or contact Joseph E. Levi, Esq.
- 01/24/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/24/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc.(SAVA) Shareholders
- NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 01/24/2025
|
Investors who lost money on Cassava Sciences, Inc. (SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / January 23, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124766&wire=1 or contact Joseph E. Levi, Esq.
- 01/23/2025
|
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESS Newswire / January 23, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124757&wire=1 or contact Joseph E. Levi, Esq.
- 01/23/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, LA / ACCESS Newswire / January 23, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM:SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 01/23/2025
|
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / January 23, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124740&wire=1 or contact Joseph E. Levi, Esq.
- 01/23/2025
|
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.
- RADNOR, Pa. , Jan. 23, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period").
- 01/23/2025
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / January 23, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124700&wire=1 or contact Joseph E. Levi, Esq.
- 01/23/2025
|
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cassava To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cassava between February 7, 2024 and November 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Jan. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the February 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 01/23/2025
|
Investors who lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESS Newswire / January 23, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124567&wire=1 or contact Joseph E. Levi, Esq.
- 01/23/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Cassava Sciences, Inc. to Contact the Firm Today!
- NEW YORK CITY, NY / ACCESS Newswire / January 23, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/23/2025
|
The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK , Jan. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/23/2025
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join – Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 22, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124529&wire=1 or contact Joseph E. Levi, Esq.
- 01/22/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.
- 01/22/2025
|
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124513&wire=1 or contact Joseph E. Levi, Esq.
- 01/22/2025
|
ROSEN, A LEADING NATIONAL FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 01/22/2025
|
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
- NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
- 01/22/2025
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - SAVA
- NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124389&wire=1 or contact Joseph E. Levi, Esq.
- 01/22/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc. (SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124359&wire=1 or contact Joseph E. Levi, Esq.
- 01/22/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/22/2025
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124297&wire=1 or contact Joseph E. Levi, Esq.
- 01/22/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Cassava Sciences, Inc. to Contact the Firm Today!
- NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/22/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
- NEW YORK, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124272&wire=1 or contact Joseph E. Levi, Esq.
- 01/21/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. – SAVA
- NEW ORLEANS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.
- 01/21/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 – SAVA
- NEW YORK, NY / ACCESSWIRE / January 21, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124221&wire=1 or contact Joseph E. Levi, Esq.
- 01/21/2025
|
SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 01/21/2025
|
Investors who Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky About Pending Class Action - SAVA
- NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124171&wire=1 or contact Joseph E. Levi, Esq.
- 01/21/2025
|
Cassava Sciences, Inc. Investors: February 10, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
- RADNOR, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, 2025.
- 01/21/2025
|
Shareholders that Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky About Pending Class Action - SAVA
- NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124151&wire=1 or contact Joseph E. Levi, Esq.
- 01/21/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/21/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SAVA
- NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).
- 01/21/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124109&wire=1 or contact Joseph E. Levi, Esq.
- 01/21/2025
|
Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / January 21, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124033&wire=1 or contact Joseph E. Levi, Esq.
- 01/21/2025
|
SAVA Stockholders Have Opportunity to Lead Cassava Sciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/21/2025
|
Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SAVA
- NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 01/21/2025
|
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / January 20, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=124000&wire=1 or contact Joseph E. Levi, Esq.
- 01/20/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Shareholders
- NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123879&wire=1 or contact Joseph E. Levi, Esq.
- 01/20/2025
|
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cassava To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / If you purchased or acquired securities in Cassava between February 7, 2024 and November 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA) and reminds investors of the February 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 01/20/2025
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123780&wire=1 or contact Joseph E. Levi, Esq.
- 01/20/2025
|
SAVA Shareholders Have Opportunity to Lead Cassava Sciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/20/2025
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
- NEW YORK , Jan. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/20/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESS Newswire / January 19, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123751&wire=1 or contact Joseph E. Levi, Esq.
- 01/19/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESS Newswire / January 19, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123724&wire=1 or contact Joseph E. Levi, Esq.
- 01/19/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Jan. 19, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers.
- 01/19/2025
|
SAVA Announcement: Kessler Topaz Meltzer & Check, LLP Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit
- RADNOR, PA / ACCESS Newswire / January 19, 2025 / The law firm of Kessler Topaz Meltzer & Check, LLP(www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava") (NASDAQ:SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period"). The lead plaintiff deadline is February 10, 2025.
- 01/19/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc.(SAVA) Shareholders
- NEW YORK, NY / ACCESSWIRE / January 19, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123646&wire=1 or contact Joseph E. Levi, Esq.
- 01/19/2025
|
SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK CITY, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/19/2025
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK, NY / ACCESSWIRE / January 18, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123611&wire=1 or contact Joseph E. Levi, Esq.
- 01/18/2025
|
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Jan. 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 01/18/2025
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESSWIRE / January 18, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123595&wire=1 or contact Joseph E. Levi, Esq.
- 01/18/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA
- NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/18/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS , Jan. 17, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 01/17/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123547&wire=1 or contact Joseph E. Levi, Esq.
- 01/17/2025
|
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
- NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / WHY: New York, N.Y., January 17, 2025.
- 01/17/2025
|
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123512&wire=1 or contact Joseph E. Levi, Esq.
- 01/17/2025
|
SAVA Announcement: Kessler Topaz Meltzer & Check, LLP Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit
- RADNOR, PA / ACCESS Newswire / January 17, 2025 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava") (NASDAQ:SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period"). The lead plaintiff deadline is February 10, 2025.
- 01/17/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / January 17, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123404&wire=1 or contact Joseph E. Levi, Esq.
- 01/17/2025
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESS Newswire / January 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/17/2025
|
Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK , Jan. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 01/17/2025
|
SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 01/16/2025
|
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
- NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
- 01/16/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/16/2025
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact The Gross Law Firm
- NEW YORK , Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/16/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123253&wire=1 or contact Joseph E. Levi, Esq.
- 01/15/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, Jan. 15, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.
- 01/15/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123233&wire=1 or contact Joseph E. Levi, Esq.
- 01/15/2025
|
SAVA Announcement: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. (SAVA)
- RADNOR, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, 2025.
- 01/15/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
- NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=123174&wire=1 or contact Joseph E. Levi, Esq.
- 01/15/2025
|
ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 01/15/2025
|
Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).
- 01/15/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122997&wire=1 or contact Joseph E. Levi, Esq.
- 01/15/2025
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/15/2025
|
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122978&wire=1 or contact Joseph E. Levi, Esq.
- 01/14/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.
- 01/14/2025
|
Lost Money on Cassava Sciences, Inc. (SAVA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122969&wire=1 or contact Joseph E. Levi, Esq.
- 01/14/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122957&wire=1 or contact Joseph E. Levi, Esq.
- 01/14/2025
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122810&wire=1 or contact Joseph E. Levi, Esq.
- 01/14/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122747&wire=1 or contact Joseph E. Levi, Esq.
- 01/14/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/14/2025
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK , Jan. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 01/14/2025
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122683&wire=1 or contact Joseph E. Levi, Esq.
- 01/13/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, LA / ACCESSWIRE / January 13, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM:SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 01/13/2025
|
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
- NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122655&wire=1 or contact Joseph E. Levi, Esq.
- 01/13/2025
|
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 – SAVA
- NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122627&wire=1 or contact Joseph E. Levi, Esq.
- 01/13/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers.
- 01/13/2025
|
Shareholders that Lost Money on Cassava Sciences, Inc. (SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122607&wire=1 or contact Joseph E. Levi, Esq.
- 01/13/2025
|
Kessler Topaz Meltzer & Check, LLP Reminds SAVA Investors of February 10, 2025 Deadline in Securities Fraud Class Action and Urges Investors with Losses to Contact the Firm
- RADNOR, Pa. , Jan. 13, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period").
- 01/13/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122603&wire=1 or contact Joseph E. Levi, Esq.
- 01/13/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
- NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
- 01/13/2025
|
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122473&wire=1 or contact Joseph E. Levi, Esq.
- 01/13/2025
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/13/2025
|
Contact The Gross Law Firm by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences, Inc.(SAVA)
- NEW YORK , Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/13/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / January 12, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122379&wire=1 or contact Joseph E. Levi, Esq.
- 01/12/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA
- NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/12/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESSWIRE / January 12, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122313&wire=1 or contact Joseph E. Levi, Esq.
- 01/12/2025
|
Investors who lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / January 12, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122276&wire=1 or contact Joseph E. Levi, Esq.
- 01/12/2025
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/12/2025
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK, NY / ACCESSWIRE / January 11, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122232&wire=1 or contact Joseph E. Levi, Esq.
- 01/11/2025
|
SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- NEW YORK , Jan. 11, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 01/11/2025
|
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Jan. 11, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 01/11/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS , Jan. 10, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Texas.
- 01/10/2025
|
Lost Money on Cassava Sciences, Inc. (SAVA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122138&wire=1 or contact Joseph E. Levi, Esq.
- 01/10/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122110&wire=1 or contact Joseph E. Levi, Esq.
- 01/10/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK CITY, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/10/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=122073&wire=1 or contact Joseph E. Levi, Esq.
- 01/10/2025
|
Shareholders that lost money on Cassava Sciences, Inc. (SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121948&wire=1 or contact Joseph E. Levi, Esq.
- 01/10/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/10/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK , Jan. 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 01/10/2025
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121902&wire=1 or contact Joseph E. Levi, Esq.
- 01/09/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 – SAVA
- NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121879&wire=1 or contact Joseph E. Levi, Esq.
- 01/09/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, LA / ACCESSWIRE / January 9, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM:SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 01/09/2025
|
Contact Levi & Korsinsky by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences, Inc. (SAVA)
- NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121852&wire=1 or contact Joseph E. Levi, Esq.
- 01/09/2025
|
Cassava Sciences, Inc. (SAVA) Investors: February 10, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
- RADNOR, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, 2025.
- 01/09/2025
|
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121796&wire=1 or contact Joseph E. Levi, Esq.
- 01/09/2025
|
ROSEN, A LONGSTANDING FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
- NEW YORK CITY, NY / ACCESSWIRE / January 9, 2025 / WHY: New York, N.Y., January 9, 2025.
- 01/09/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESSWIRE / January 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121678&wire=1 or contact Joseph E. Levi, Esq.
- 01/09/2025
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / January 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/09/2025
|
Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK , Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/09/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121639&wire=1 or contact Joseph E. Levi, Esq.
- 01/08/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, Jan. 08, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.
- 01/08/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit – SAVA
- NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
- 01/08/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK , Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/08/2025
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / January 8, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121424&wire=1 or contact Joseph E. Levi, Esq.
- 01/08/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/08/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
- NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121401&wire=1 or contact Joseph E. Levi, Esq.
- 01/07/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.
- 01/07/2025
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121377&wire=1 or contact Joseph E. Levi, Esq.
- 01/07/2025
|
Contact Levi & Korsinsky by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences, Inc. (SAVA)
- NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121340&wire=1 or contact Joseph E. Levi, Esq.
- 01/07/2025
|
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cassava To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Cassava between February 7, 2024 and November 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA) and reminds investors of the February 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 01/07/2025
|
Cassava Sciences, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; February 10, 2025 Deadline to file Lead Plaintiff Motion
- Investors can contact the law firm at no cost to learn more about recovering their losses
- 01/07/2025
|
Cassava Sciences Provides a Business Update
- Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease expected late first-quarter/early second-quarter 2025
- 01/07/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121311&wire=1 or contact Joseph E. Levi, Esq.
- 01/07/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers.
- 01/07/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121288&wire=1 or contact Joseph E. Levi, Esq.
- 01/07/2025
|
Cassava Sciences, Inc. (SAVA) Investors: February 10, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
- RADNOR, PA / ACCESSWIRE / January 7, 2025 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. ("Cassava") (NASDAQ:SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period"). The lead plaintiff deadline is February 10, 2025.
- 01/07/2025
|
Shareholders that lost money on Cassava Sciences, Inc. (SAVA) should contact The Gross Law Firm about pending Class Action - SAVA
- NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).
- 01/07/2025
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121168&wire=1 or contact Joseph E. Levi, Esq.
- 01/07/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / January 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/07/2025
|
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 01/07/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit – SAVA
- NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121111&wire=1 or contact Joseph E. Levi, Esq.
- 01/06/2025
|
Robbins LLP Reminds Investors of the Pending Class Action Against Cassava Sciences, Inc. and Urges SAVA Stockholders to Contact the Firm for Information
- SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for wrongdoing between February 7, 2024 and November 24, 2024. Cassava is a clinical stage biotechnology company, with a focus on developing drugs for neurodegenerative diseases.
- 01/06/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
- NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121110&wire=1 or contact Joseph E. Levi, Esq.
- 01/06/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, LA / ACCESSWIRE / January 6, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM:SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 01/06/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121069&wire=1 or contact Joseph E. Levi, Esq.
- 01/06/2025
|
SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- NEW YORK , Jan. 6, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 01/06/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=121012&wire=1 or contact Joseph E. Levi, Esq.
- 01/06/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
- NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120953&wire=1 or contact Joseph E. Levi, Esq.
- 01/06/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/06/2025
|
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120811&wire=1 or contact Joseph E. Levi, Esq.
- 01/06/2025
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/06/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK , Jan. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/06/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120787&wire=1 or contact Joseph E. Levi, Esq.
- 01/05/2025
|
Class Action Announcement for SAVA Investors: A Securities Fraud Class Action Lawsuit Was Filed Against Cassava Sciences, Inc. (SAVA) - Contact Kessler Topaz Meltzer & Check, LLP
- RADNOR, Pa. , Jan. 5, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period").
- 01/05/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120749&wire=1 or contact Joseph E. Levi, Esq.
- 01/05/2025
|
ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Jan. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 01/05/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA
- NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/05/2025
|
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120675&wire=1 or contact Joseph E. Levi, Esq.
- 01/05/2025
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/05/2025
|
Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 4, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120644&wire=1 or contact Joseph E. Levi, Esq.
- 01/04/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESSWIRE / January 4, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120632&wire=1 or contact Joseph E. Levi, Esq.
- 01/04/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS , Jan. 3, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 01/03/2025
|
Class Action Announcement for Cassava Sciences, Inc. Investors: A Securities Fraud Class Action Lawsuit Was Filed Against Cassava Sciences, Inc.
- RADNOR, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, 2025.
- 01/03/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/03/2025
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120427&wire=1 or contact Joseph E. Levi, Esq.
- 01/03/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Shareholders
- NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120418&wire=1 or contact Joseph E. Levi, Esq.
- 01/03/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/03/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK , Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 01/03/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
- NEW YORK, NY / ACCESSWIRE / January 3, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120382&wire=1 or contact Joseph E. Levi, Esq.
- 01/03/2025
|
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 01/02/2025
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, LA / ACCESSWIRE / January 2, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM:SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 01/02/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120320&wire=1 or contact Joseph E. Levi, Esq.
- 01/02/2025
|
Robbins LLP Reminds Investors of the Cassava Sciences, Inc. (SAVA) Class Action and Urges Investors with Large Losses to Contact the Firm for Information
- SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for wrongdoing between February 7, 2024 and November 24, 2024. Cassava is a clinical stage biotechnology company, with a focus on developing drugs for neurodegenerative diseases.
- 01/02/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120184&wire=1 or contact Joseph E. Levi, Esq.
- 01/02/2025
|
Cassava Sciences, Inc. Class Action: The Gross Law Firm Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK , Jan. 2, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 01/02/2025
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc. (SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120160&wire=1 or contact Joseph E. Levi, Esq.
- 01/02/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK , Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 01/02/2025
|
Contact Levi & Korsinsky by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences, Inc. (SAVA)
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120075&wire=1 or contact Joseph E. Levi, Esq.
- 01/02/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Cassava Sciences, Inc. to Contact the Firm Today!
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/02/2025
|
SAVA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 01/02/2025
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119926&wire=1 or contact Joseph E. Levi, Esq.
- 01/02/2025
|
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119904&wire=1 or contact Joseph E. Levi, Esq.
- 01/02/2025
|
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119883&wire=1 or contact Joseph E. Levi, Esq.
- 01/02/2025
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119951&wire=1 or contact Joseph E. Levi, Esq.
- 01/02/2025
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120010&wire=1 or contact Joseph E. Levi, Esq.
- 01/02/2025
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / January 2, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119978&wire=1 or contact Joseph E. Levi, Esq.
- 01/02/2025
|
Investors who lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / January 1, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=120042&wire=1 or contact Joseph E. Levi, Esq.
- 01/02/2025
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Jan. 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers.
- 01/01/2025
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 31, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119803&wire=1 or contact Joseph E. Levi, Esq.
- 12/31/2024
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK, NY / ACCESSWIRE / December 31, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119753&wire=1 or contact Joseph E. Levi, Esq.
- 12/31/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA
- NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 12/31/2024
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / December 31, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119637&wire=1 or contact Joseph E. Levi, Esq.
- 12/31/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Cassava Sciences, Inc. to Contact the Firm Today!
- NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/31/2024
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK , Dec. 31, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 12/31/2024
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119578&wire=1 or contact Joseph E. Levi, Esq.
- 12/30/2024
|
ROSEN, A TOP-RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Dec. 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 12/30/2024
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, LA / ACCESSWIRE / December 30, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM:SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 12/30/2024
|
Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SAVA
- NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119499&wire=1 or contact Joseph E. Levi, Esq.
- 12/30/2024
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc. (SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
- 12/30/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 12/30/2024
|
Shareholders that lost money on Cassava Sciences, Inc. (SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119431&wire=1 or contact Joseph E. Levi, Esq.
- 12/30/2024
|
SAVA Investor Alert: Contact Kessler Topaz Meltzer & Check, LLP About the Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. (SAVA)
- RADNOR, Pa. , Dec. 30, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the "Class Period").
- 12/30/2024
|
Investors who Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky About Pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / December 30, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119372&wire=1 or contact Joseph E. Levi, Esq.
- 12/30/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Cassava Sciences, Inc. to Contact the Firm Today!
- NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/30/2024
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The Gross Law Firm
- NEW YORK , Dec. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 12/30/2024
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc.(SAVA) Shareholders
- NEW YORK, NY / ACCESSWIRE / December 29, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119319&wire=1 or contact Joseph E. Levi, Esq.
- 12/29/2024
|
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 29, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119287&wire=1 or contact Joseph E. Levi, Esq.
- 12/29/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 12/29/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
- NEW YORK, NY / ACCESSWIRE / December 29, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119227&wire=1 or contact Joseph E. Levi, Esq.
- 12/29/2024
|
SAVA Stockholders Have Opportunity to Lead Cassava Sciences, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/29/2024
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESSWIRE / December 28, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119147&wire=1 or contact Joseph E. Levi, Esq.
- 12/28/2024
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 28, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119144&wire=1 or contact Joseph E. Levi, Esq.
- 12/28/2024
|
SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- NEW YORK, Dec. 28, 2024 /PRNewswire/ -- aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to Cassava's drug prospects and anticipated growth while also minimizing risk from a potential drug failure. Yet, in truth, Cassava's repeated statements of confidence in simufilam, Cassava's leading drug candidate, and reliance upon spinning the statistically insignificant data from the Phase 2 study fell short of the reality of simufilam's potential; Cassava simply did not have a drug that was capable of abating the progression of Alzheimer's Disease, even when attempting to treat only the mild and moderate cases. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Cassava class action, go to https://rosenlegal.com/submit-form/?case_id=22374 https://rosenlegal.com/submit-form/?case_id=28116 call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View original content to download multimedia:https://www.prnewswire.com/news-releases/sava-investors-have-opportunity-to-lead-cassava-sciences-inc-securities-fraud-lawsuit-302339014.html SOURCE THE ROSEN LAW FIRM, P. A.
- 12/28/2024
|
SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- NEW YORK , Dec. 28, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 12/28/2024
|
CASSAVA SCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS , Dec. 27, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Texas.
- 12/27/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVA
- NEW YORK, NY / ACCESSWIRE / December 27, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119113&wire=1 or contact Joseph E. Levi, Esq.
- 12/27/2024
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc. (SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / December 27, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119104&wire=1 or contact Joseph E. Levi, Esq.
- 12/27/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK , Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 12/27/2024
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / December 27, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119053&wire=1 or contact Joseph E. Levi, Esq.
- 12/27/2024
|
Class Action Announcement for Cassava Sciences, Inc. (SAVA): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc.
- RADNOR, Pa., Dec. 27, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, 2025.
- 12/27/2024
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESSWIRE / December 27, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119050&wire=1 or contact Joseph E. Levi, Esq.
- 12/27/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
- NEW YORK, NY / ACCESSWIRE / December 27, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=119022&wire=1 or contact Joseph E. Levi, Esq.
- 12/27/2024
|
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 12/27/2024
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESSWIRE / December 27, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118912&wire=1 or contact Joseph E. Levi, Esq.
- 12/27/2024
|
SAVA Shareholders Have Opportunity to Lead Cassava Sciences, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK, NY / ACCESSWIRE / December 27, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/27/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK , Dec. 27, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 12/27/2024
|
Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / December 27, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118869&wire=1 or contact Joseph E. Levi, Esq.
- 12/27/2024
|
SAVA Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.
- RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is February 10, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered.
- 12/26/2024
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, LA / ACCESSWIRE / December 26, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM:SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 12/26/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK--(BUSINESS WIRE)---- $SAVA #CassavaSciences--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava.
- 12/26/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118691&wire=1 or contact Joseph E. Levi, Esq.
- 12/26/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 12/26/2024
|
Investors who lost money on Cassava Sciences, Inc. (SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118661&wire=1 or contact Joseph E. Levi, Esq.
- 12/26/2024
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118637&wire=1 or contact Joseph E. Levi, Esq.
- 12/26/2024
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118614&wire=1 or contact Joseph E. Levi, Esq.
- 12/26/2024
|
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118593&wire=1 or contact Joseph E. Levi, Esq.
- 12/26/2024
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118570&wire=1 or contact Joseph E. Levi, Esq.
- 12/26/2024
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118549&wire=1 or contact Joseph E. Levi, Esq.
- 12/26/2024
|
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118531&wire=1 or contact Joseph E. Levi, Esq.
- 12/26/2024
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc. (SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118518&wire=1 or contact Joseph E. Levi, Esq.
- 12/26/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118505&wire=1 or contact Joseph E. Levi, Esq.
- 12/26/2024
|
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118759&wire=1 or contact Joseph E. Levi, Esq.
- 12/26/2024
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/26/2024
|
The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK , Dec. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 12/26/2024
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118719&wire=1 or contact Joseph E. Levi, Esq.
- 12/26/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK , Dec. 25, 2024 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/25/2024
|
Shareholders that lost money on Cassava Sciences, Inc. (SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / December 24, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118476&wire=1 or contact Joseph E. Levi, Esq.
- 12/24/2024
|
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 12/24/2024
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join – Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / December 24, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118457&wire=1 or contact Joseph E. Levi, Esq.
- 12/24/2024
|
SAVA Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against Cassava Sciences, Inc.
- SAN DIEGO, CA / ACCESSWIRE / December 24, 2024 / Robbins LLP reminds investors that a class action was filed against Cassava Sciences, Inc. (NASDAQ:SAVA) for wrongdoing between February 7, 2024 and November 24, 2024. Cassava is a clinical stage biotechnology company, with a focus on developing drugs for neurodegenerative diseases.
- 12/24/2024
|
Lost Money on Cassava Sciences, Inc. (SAVA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / December 24, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118437&wire=1 or contact Joseph E. Levi, Esq.
- 12/24/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 12/24/2024
|
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 24, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118346&wire=1 or contact Joseph E. Levi, Esq.
- 12/24/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/24/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/24/2024
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 – SAVA
- NEW YORK, NY / ACCESSWIRE / December 23, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118309&wire=1 or contact Joseph E. Levi, Esq.
- 12/23/2024
|
CASSAVA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc and Encourages Investors to Contact the Firm
- NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Cassava Sciences, Inc (“Cassava” or the “Company”) (NASDAQ: SAVA) in the United States District Court for the Western District of Texas on behalf of all persons and entities who purchased or otherwise acquired Cassava securities between February 7, 2024 to November 24, 2024, both dates inclusive (the “Class Period”). Investors have until February 10, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- 12/23/2024
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit – SAVA
- NEW YORK, NY / ACCESSWIRE / December 23, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118298&wire=1 or contact Joseph E. Levi, Esq.
- 12/23/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA
- NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 12/23/2024
|
Contact Levi & Korsinsky by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences, Inc. (SAVA)
- NEW YORK, NY / ACCESSWIRE / December 23, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118277&wire=1 or contact Joseph E. Levi, Esq.
- 12/23/2024
|
SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- NEW YORK , Dec. 23, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 12/23/2024
|
Investors who lost money on Cassava Sciences, Inc. (SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / December 23, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118236&wire=1 or contact Joseph E. Levi, Esq.
- 12/23/2024
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESSWIRE / December 23, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118111&wire=1 or contact Joseph E. Levi, Esq.
- 12/23/2024
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/23/2024
|
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK , Dec. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 12/23/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 22, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117985&wire=1 or contact Joseph E. Levi, Esq.
- 12/22/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/22/2024
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 21, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117940&wire=1 or contact Joseph E. Levi, Esq.
- 12/21/2024
|
Investors who lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / December 21, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117927&wire=1 or contact Joseph E. Levi, Esq.
- 12/21/2024
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS , Dec. 20, 2024 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 12/20/2024
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors – Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / December 20, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117904&wire=1 or contact Joseph E. Levi, Esq.
- 12/20/2024
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / December 20, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117874&wire=1 or contact Joseph E. Levi, Esq.
- 12/20/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 12/20/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers.
- 12/20/2024
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESSWIRE / December 20, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117814&wire=1 or contact Joseph E. Levi, Esq.
- 12/20/2024
|
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
- 12/20/2024
|
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / December 20, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117787&wire=1 or contact Joseph E. Levi, Esq.
- 12/20/2024
|
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cassava To Contact Him Directly To Discuss Their Options
- 12/20/2024
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / December 20, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117730&wire=1 or contact Joseph E. Levi, Esq.
- 12/20/2024
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / December 20, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/20/2024
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 12/20/2024
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / December 19, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117692&wire=1 or contact Joseph E. Levi, Esq.
- 12/19/2024
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, LA / ACCESSWIRE / December 19, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM:SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 12/19/2024
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESSWIRE / December 19, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117681&wire=1 or contact Joseph E. Levi, Esq.
- 12/19/2024
|
Cassava Sciences, Inc. Stockholder Alert: Robbins LLP Reminds Investors of the SAVA Class Action
- SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for wrongdoing between February 7, 2024 and November 24, 2024. Cassava is a clinical stage biotechnology company, with a focus on developing drugs for neurodegenerative diseases.
- 12/19/2024
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / December 19, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117672&wire=1 or contact Joseph E. Levi, Esq.
- 12/19/2024
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 – SAVA
- NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
- 12/19/2024
|
Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SAVA
- NEW YORK, NY / ACCESSWIRE / December 19, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117581&wire=1 or contact Joseph E. Levi, Esq.
- 12/19/2024
|
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 19, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117510&wire=1 or contact Joseph E. Levi, Esq.
- 12/19/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/19/2024
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The Gross Law Firm
- NEW YORK , Dec. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 12/19/2024
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / December 18, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117471&wire=1 or contact Joseph E. Levi, Esq.
- 12/18/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Cassava Sciences, Inc. - SAVA
- NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
- 12/18/2024
|
Investors who Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky about Pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / December 18, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117443&wire=1 or contact Joseph E. Levi, Esq.
- 12/18/2024
|
SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- NEW YORK , Dec. 18, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
- 12/18/2024
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 – SAVA
- NEW YORK, NY / ACCESSWIRE / December 18, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117408&wire=1 or contact Joseph E. Levi, Esq.
- 12/18/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK--(BUSINESS WIRE)---- $SAVA #CassavaSciences--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava.
- 12/18/2024
|
February 10, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against SAVA
- NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).
- 12/18/2024
|
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 18, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117351&wire=1 or contact Joseph E. Levi, Esq.
- 12/18/2024
|
Investors who Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky About Pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / December 18, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117347&wire=1 or contact Joseph E. Levi, Esq.
- 12/18/2024
|
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Cassava To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Cassava between February 7, 2024 and November 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Dec. 18, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the February 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 12/18/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 18, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117332&wire=1 or contact Joseph E. Levi, Esq.
- 12/18/2024
|
CASSAVA SCIENCES, INC. (NASDAQ: SAVA) INVESTOR ALERT: Investors With Large Losses in Cassava Sciences, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
- NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, inclusive. For more information, submit a form at Cassava Sciences, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.
- 12/18/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 18, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117242&wire=1 or contact Joseph E. Levi, Esq.
- 12/18/2024
|
SAVA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/18/2024
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / December 17, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117212&wire=1 or contact Joseph E. Levi, Esq.
- 12/17/2024
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.
- 12/17/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 17, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117190&wire=1 or contact Joseph E. Levi, Esq.
- 12/17/2024
|
CASSAVA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc and Encourages Investors to Contact the Firm
- NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Cassava Sciences, Inc (“Cassava” or the “Company”) (NASDAQ: SAVA) in the United States District Court for the Western District of Texas on behalf of all persons and entities who purchased or otherwise acquired Cassava securities between February 7, 2024 to November 24, 2024, both dates inclusive (the “Class Period”). Investors have until February 10, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- 12/17/2024
|
Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – SAVA
- NEW YORK, NY / ACCESSWIRE / December 17, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117176&wire=1 or contact Joseph E. Levi, Esq.
- 12/17/2024
|
ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 10, 2025.
- 12/17/2024
|
Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SAVA
- NEW YORK, NY / ACCESSWIRE / December 17, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117148&wire=1 or contact Joseph E. Levi, Esq.
- 12/17/2024
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / December 17, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117132&wire=1 or contact Joseph E. Levi, Esq.
- 12/17/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK , Dec. 17, 2024 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/17/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 17, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117056&wire=1 or contact Joseph E. Levi, Esq.
- 12/17/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
- NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/17/2024
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / December 17, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116995&wire=1 or contact Joseph E. Levi, Esq.
- 12/17/2024
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/17/2024
|
Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SAVA
- NEW YORK , Dec. 17, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cassava Sciences, Inc. investors who were adversely affected by alleged securities fraud between February 7, 2024 and November 24, 2024.
- 12/17/2024
|
Investors who lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / December 16, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116956&wire=1 or contact Joseph E. Levi, Esq.
- 12/16/2024
|
CASSAVA SCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS, LA / ACCESSWIRE / December 16, 2024 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM:SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the "Class Period").
- 12/16/2024
|
Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / December 16, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116942&wire=1 or contact Joseph E. Levi, Esq.
- 12/16/2024
|
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Cassava Sciences, Inc.
- SAN DIEGO , Dec. 16, 2024 /PRNewswire/ -- Robbins LLP announces that a class action was filed on behalf of all investors who purchased or otherwise acquired Cassava Sciences, Inc. (NASDAQ: SAVA) securities between February 7, 2024 and November 24, 2024. Cassava is a clinical stage biotechnology company, with a focus on developing drugs for neurodegenerative diseases.
- 12/16/2024
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc.(SAVA) Shareholders
- NEW YORK, NY / ACCESSWIRE / December 16, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116897&wire=1 or contact Joseph E. Levi, Esq.
- 12/16/2024
|
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc. (SAVA)
- NEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Western District of Texas on behalf of all persons or entities who purchased or otherwise acquired Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities between February 7, 2024 to November 24, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company's investors under the federal securities laws.
- 12/16/2024
|
Contact Levi & Korsinsky by February 10, 2025 Deadline to Join Class Action Against Cassava Sciences, Inc. (SAVA)
- NEW YORK, NY / ACCESSWIRE / December 16, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116877&wire=1 or contact Joseph E. Levi, Esq.
- 12/16/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVA
- NEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
- 12/16/2024
|
Shareholders that Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky About Pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / December 16, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116872&wire=1 or contact Joseph E. Levi, Esq.
- 12/16/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CassavaSciences, Inc. - SAVA
- NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/16/2024
|
Cassava Sciences, Inc. Class Action: Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 10, 2025 - SAVA
- NEW YORK, NY / ACCESSWIRE / December 16, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116757&wire=1 or contact Joseph E. Levi, Esq.
- 12/16/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/16/2024
|
Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join - Contact The Gross Law Firm
- NEW YORK , Dec. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 12/16/2024
|
CASSAVA SCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Cou.
- 12/15/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 15, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116663&wire=1 or contact Joseph E. Levi, Esq.
- 12/15/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CassavaSciences, Inc. - SAVA
- NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/15/2024
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
- NEW YORK, NY / ACCESSWIRE / December 15, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116647&wire=1 or contact Joseph E. Levi, Esq.
- 12/15/2024
|
Shareholders of Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 15, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116608&wire=1 or contact Joseph E. Levi, Esq.
- 12/15/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/15/2024
|
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
- NEW YORK, NY / ACCESSWIRE / December 14, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116552&wire=1 or contact Joseph E. Levi, Esq.
- 12/14/2024
|
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
- NEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 10, 2025.
- 12/14/2024
|
SAVA Investors with Losses in Excess of $100K Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- NEW YORK , Dec. 13, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.
- 12/13/2024
|
Shareholders that Lost Money on Cassava Sciences, Inc. (SAVA) Should Contact Levi & Korsinsky about Pending Class Action - SAVA
- NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116534&wire=1 or contact Joseph E. Levi, Esq.
- 12/13/2024
|
Investors in Cassava Sciences, Inc. Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA
- NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116524&wire=1 or contact Joseph E. Levi, Esq.
- 12/13/2024
|
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers.
- 12/13/2024
|
Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights
- NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024. Cassava describes itself as a “clinical stage biotechnology company, with a focus on developing drugs for neurodegenerative diseases.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The A.
- 12/13/2024
|
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
- NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116468&wire=1 or contact Joseph E. Levi, Esq.
- 12/13/2024
|
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Cassava Sciences, Inc. (SAVA) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
- ATLANTA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA). The lawsuit alleges that Defendants created a false impression that they possessed reliable information pertaining to the Company's drug prospects and anticipated growth while also minimizing risk from a potential drug failure.
- 12/13/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CassavaSciences, Inc. - SAVA
- NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/13/2024
|
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / December 13, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=116451&wire=1 or contact Joseph E. Levi, Esq.
- 12/13/2024
|
SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
- 12/13/2024
|
Levi & Korsinsky Reminds Cassava Sciences, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - SAVA
- NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 12/11/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CassavaSciences, Inc. - SAVA
- NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/11/2024
|
Cassava Sciences, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SAVA
- NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 12/10/2024
|
Bronstein, Gewirtz & Grossman, LLC Encourages Cassava Sciences, Inc. (SAVA) Shareholders to Inquire about Securities Investigation
- NEW YORK CITY, NY / ACCESSWIRE / December 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
- 12/10/2024
|
SAVA STOCK ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of an Ongoing Investigation
- NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 12/09/2024
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Shareholders to Connect
- NEW YORK CITY, NY / ACCESSWIRE / December 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
- 12/09/2024
|
Cassava Sciences, Inc. (SAVA) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
- NEW YORK, NY / ACCESSWIRE / December 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 12/08/2024
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cassava Sciences, Inc. (SAVA) And Encourages Shareholders to Reach Out
- NEW YORK CITY, NY / ACCESSWIRE / December 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
- 12/08/2024
|
Did Cassava Sciences, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SAVA
- NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 12/06/2024
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cassava Sciences, Inc. (SAVA) and Encourages Shareholders to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESSWIRE / December 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
- 12/06/2024
|
SAVA STOCK ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of an Ongoing Investigation
- NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 12/05/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CassavaSciences, Inc. - SAVA
- NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/05/2024
|
Cassava Sciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Cassava Sciences, Inc. (SAVA)
- NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 12/05/2024
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cassava Sciences, Inc. (SAVA) and Encourages Investors to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESSWIRE / December 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
- 12/05/2024
|
ATTENTION Cassava Sciences, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
- NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 12/04/2024
|
Cassava Sciences, Inc. (SAVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESSWIRE / December 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
- 12/04/2024
|
ATTENTION Cassava Sciences, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
- NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 12/03/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
- NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/03/2024
|
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cassava Sciences, Inc. (SAVA) Regarding Possible Securities Fraud Violations
- NEW YORK, NY / ACCESSWIRE / December 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 12/01/2024
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cassava Sciences, Inc. (SAVA) and Encourages Investors to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESSWIRE / December 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
- 12/01/2024
|
Cassava Sciences, Inc. Being Investigated on Behalf of Cassava Sciences, Inc. Investors. Contact Levi & Korsinsky For Details
- NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 11/29/2024
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cassava Sciences, Inc. (SAVA) And Encourages Investors to Reach Out
- NEW YORK CITY, NY / ACCESSWIRE / November 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
- 11/29/2024
|
Cassava Sciences, Inc. Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SAVA
- NEW YORK, NY / ACCESSWIRE / November 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 11/28/2024
|
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cassava Sciences, Inc. (SAVA) And Encourages Stockholders to Reach Out
- NEW YORK CITY, NY / ACCESSWIRE / November 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
- 11/28/2024
|
ATTENTION SAVA SHAREHOLDERS: Investors who Lost Money on Cassava Sciences, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
- NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 11/27/2024
|
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cassava Sciences, Inc. (SAVA) And Encourages Stockholders to Connect
- NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
- 11/27/2024
|
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
- Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.
- 11/26/2024
|
ATTENTION Cassava Sciences, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
- NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 11/26/2024
|
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)
- Cassava Sciences (SAVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 11/26/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
- NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/26/2024
|
ATTENTION Cassava Sciences, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
- NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 11/26/2024
|
Cassava Sciences, Inc. (SAVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
- 11/26/2024
|
Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer's drug flops
- In March, pharmaceutical company Cassava Sciences made headlines for a report by the Food and Drug Administration (FDA) that cast doubt on the positive trial results of its novel Alzheimer's drug, simufilam.
- 11/26/2024
|
SAVA ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cassava Sciences, Inc. Shareholders Who Lost Money
- NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 11/25/2024
|
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cassava Sciences, Inc. (SAVA) and Encourages Stockholders to Learn More About the Investigation
- NEW YORK CITY, NY / ACCESSWIRE / November 25, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA). Investors who purchased Cassava securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAVA.
- 11/25/2024
|
Did Cassava Sciences, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SAVA
- NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava Sciences, Inc. ("Cassava Sciences, Inc.") (NASDAQ:SAVA) concerning possible violations of federal securities laws. On November 25, 2024, Cassava "today announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD [Alzheimer's Disease] did not meet each of the pre-specified co-primary, secondary and exploratory biomarker endpoints.
- 11/25/2024
|
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update
- Cassava Sciences SAVA stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market.
- 11/25/2024
|
Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops
- Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. The post Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops appeared first on Investor's Business Daily.
- 11/25/2024
|
Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study
- Cassava Sciences (SAVA) shares are plunging in premarket trading and are losing most of their value after the biotech firm said its experimental Simufilam drug—aimed at treating Alzheimer's disease (AD)—failed to show a “significant reduction in cognitive or functional decline” during the Phase 3 trial of the treatment.
- 11/25/2024
|
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
- Cassava Sciences Inc. SAVA stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer's disease.
- 11/25/2024
|
Cassava Sciences' stock craters after Alzheimer's disease trial fails to meet its goals
- The biotech says it will discontinue a second trial but will still offer full analyses of the data.
- 11/25/2024
|
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- U.S. stock futures were higher this morning, with the Dow futures gaining more than 300 points on Monday.
- 11/25/2024
|
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
- Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer's disease in the ReThink-ALZ Phase 3 study
- 11/25/2024
|
Cassava Sciences to Hold Corporate Update on November 25th
- AUSTIN, Texas, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today announced it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. Eastern Time.
- 11/24/2024
|
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
- Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs
- 11/18/2024
|
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?
- Here is how Cassava Sciences, Inc. (SAVA) and biote Corp. (BTMD) have performed compared to their sector so far this year.
- 11/15/2024
|
What Makes Cassava Sciences (SAVA) a New Buy Stock
- Cassava Sciences (SAVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 11/12/2024
|
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
- Panax ginseng shows the highest effectiveness in treating Alzheimer's because it inhibits nitro-oxidative stress, scavenges peroxynitrite, and reverses part of its damage, leading to sustained cognitive improvements over two years. Anavex's Blarcamesine may slow mild Alzheimer's progression due to its antioxidant capacity, with results from a 96-week trial potentially aiding regulatory approval. Cassava Sciences' Simufilam's effectiveness is limited to one year for mild Alzheimer's, with no residual effects after discontinuation, and mixed results in combined mild and moderate groups.
- 11/11/2024
|
Cassava Sciences, Inc. (SAVA) Q3 2024 Earnings Call Transcript
- Cassava Sciences, Inc. (NASDAQ:SAVA ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Rick Barry - President & Chief Executive Officer Eric Schoen - Chief Financial Officer Conference Call Participants Vernon Bernardino - H.C. Wainwright Elemer Piros - Rodman Operator Ladies and gentlemen, welcome to Cassava Sciences Report for the Third Quarter 2024.
- 11/07/2024
|
Cassava Sciences Reports Q3 2024 Financial and Operating Results
- AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer's disease, today reported financial results for the third quarter ended September 30, 2024.
- 11/07/2024
|
Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
- AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.
- 10/31/2024
|
Analysts Believe Cassava Sciences Now Has 300% Upside From Here
- Cassava Sciences Inc. NASDAQ: SAVA is a biotech developing treatments for Alzheimer's disease. The company has a lot of controversy over its lead drug, simufilam, which attempts to go further than alleviate symptoms but actually modify the underlying biology of the disease.
- 10/30/2024
|
SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims
- Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.
- 09/30/2024
|
Why Cassava Sciences Stock Dived by Almost 11% Today
- The biotech is paying $40 million not to acquire a drug or fund a development program, but to satisfy a regulator. The money is going toward a settlement with the Securities and Exchange Commission.
- 09/27/2024
|
Cassava's Stock Drops After It Agrees to Pay $40M to Settle SEC Alzheimer's Claims
- Cassava Sciences (SAVA) shares dropped more than 11% after the company agreed to a $40 million settlement with the Securities and Exchange Commission (SEC) over charges that it manipulated clinical trial data related to its Alzheimer's disease drug.
- 09/27/2024
|
SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial Data, Company And Former Execs Agree To Pay Penalty
- Alzheimer's drug developer Cassava Sciences Inc SAVA, its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company's controversial Alzheimer's drug, simufilam.
- 09/27/2024
|
Cassava Sciences settles SEC charges of ‘misleading' Alzheimer's trial claims
- Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer's clinical trial.
- 09/26/2024
|
Cassava Sciences Resolves SEC Investigation
- AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) of negligence-based disclosure charges that resolve a previously-disclosed SEC investigation into statements made by the Company pertaining to the results of its 2020 Phase 2b clinical trial of simufilam and related matters. Two former senior employees of the Company also settled negligence-based disclosure charges brought by the SEC.
- 09/26/2024
|
SEC Charges Cassava Sciences, Two Former Executives for Misleading Claims About Alzheimer's Clinical Trial
- Washington, D.C.--(Newsfile Corp. - September 26, 2024) - The Securities and Exchange Commission today announced Cassava Sciences, Inc., its founder and former CEO, Remi Barbier, and its former Senior Vice President of Neuroscience, Dr. Lindsay Burns, will pay more than $40 million to settle charges related to misleading statements made in September 2020 about the results of a Phase 2 clinical trial for the company's purported therapeutic for the treatment of Alzheimer's disease.
- 09/26/2024
|
US charges Cassava Sciences, two former executives for misleading claims about Alzheimer's clinical trial
- The U.S. Securities and Exchange Commission said on Thursday that it charged Cassava Sciences and two of the company's former executives for misleading claims about the results of Alzheimer's clinical trials.
- 09/26/2024
|
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
- AUSTIN, Texas, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced the completion of a third interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer's disease. A routine, scheduled meeting of a Data and Safety Monitoring Board (DSMB) resulted in a recommendation that both of Cassava Sciences' on-going Phase 3 studies continue as planned, without modification.
- 09/24/2024
|
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
- AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it has been invited to present at the H.C. Wainwright 26th Annual Global Investment Conference, being held in New York.
- 09/03/2024
|
Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Cassava Sciences NASDAQ: SAVA has become a hot topic among traders and active market participants thanks to its recent surge in volatility, liquidity, and overall market performance. Over the past month, shares have climbed 133% and are now more than 190% above their 52-week low.
- 08/10/2024
|
Cassava Sciences Q2 Earnings Review: So Many Questions, So Few Answers
- Cassava Sciences, Inc. announced its Q2 earnings earlier today. Management says it hopes to share pivotal Phase 3 study data for Alzheimer's drug candidate simufilam in 2024. The CEO and Head of Research resigned from the company a few weeks ago — possibly related to an ongoing SEC investigation into Cassava.
- 08/08/2024
|
2 Biotech Stocks Making Moves Today
- Last month, we took a look at three biotech stocks following a historically bullish month for biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI).
- 08/06/2024
|
Cassava Sciences News: Why Is SAVA Stock Trending Today?
- Cassava Sciences (NASDAQ: SAVA ) stock is a hot topic among traders on Tuesday alongside a few important pieces of news that investors need to know about this morning. First off, traders will note that SAVA is a trending stock today.
- 08/06/2024
|
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
- AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reflected on the passing of long-time board member Sanford Robertson.
- 08/05/2024
|
Get Your Money Out of These 3 Healthcare Stocks ASAP
- In general, I'm quite bullish on the healthcare sector. Many of the names in the space have extremely low valuations because a high percentage of investors irrationally believed that healthcare companies could never perform well when interest rates were high.
- 08/02/2024
|
Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET
- AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time.
- 08/01/2024
|
SAVA Stock: Cassava Sciences Extends Simufilam Trials as Much as 36 Months
- A struggling biotech stock is on the move today on news of a trial extension. Indeed, Cassava Sciences (NASDAQ: SAVA ) has announced that it will be extending trials of simufilam — its lead Alzheimer's disease treatment candidate — by up to 36 months.
- 07/30/2024
|
Cassava Sciences Announces Expansion of Open-Label Extension Trials
- AUSTIN, Texas, July 30, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Company will extend by up to an additional 36 months each of the open-label extension trials in its ongoing Phase 2 and Phase 3 clinical programs. These amendments to the protocols will allow patients who have previously participated in a randomized trial of simufilam in Alzheimer's disease, if they desire, to continue open-label treatment with simufilam. This expansion of the open-label extension trials offers a bridge for any gap between patients ending treatment in a clinical trial and the Company reporting to regulatory authorities the results of the ongoing, randomized, placebo-controlled Phase 3 trials. The open-label extension can continue for up to 36 months or until a new drug application for simufilam has been reviewed by FDA.
- 07/30/2024
|
Get Your Money Out of These 3 Biotech Stocks Before the End of July
- Biotech stocks are known for their high volatility and potential for massive gains. The success in the sector often hinges on progressive and often groundbreaking medical advancements.
- 07/28/2024
|
SAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial Update
- Cassava Sciences (NASDAQ: SAVA ) stock is up on Monday after the company provided investors with an update for its Phase 3 trial for its Alzheimer's disease treatment. According to a news release from Cassava Sciences, the data from its first Phase 3 clinical trial will come out by December 2024.
- 07/22/2024
|
Why Cassava Sciences Stock Is Skyrocketing Today
- New Cassava executive chairman Rick Barry wrote an open letter to stakeholders. Barry acknowledged skepticism but stressed the potential for its Alzheimer's disease candidate simufilam.
- 07/22/2024
|
SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know.
- A bad month just got much worse for Cassava Sciences (NASDAQ: SAVA ). SAVA stock is plunging today on news that President and CEO Remi Barbier is stepping down, effective immediately.
- 07/17/2024
|
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
- AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO.
- 07/17/2024
|
3 Healthcare Stocks to Sell in July Before They Crash & Burn
- The outlook of many healthcare stocks is quite positive at this point. That's partly because many large investors have shunned the sector, since they believe that it is destined to produce horrible returns as long as interest rates remain elevated.
- 07/08/2024
|
Top 5 Health Care Stocks That May Explode In July
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 07/08/2024
|
3 Biotech Stocks to Sell in July Before They Crash & Burn
- The biotech segment is a relatively new sector that combines the fields of biology and technology. It integrates natural sciences from biology and engineering aspects from technology to develop products with meaningful applications in areas like medicine, agriculture, therapeutics, and more.
- 07/05/2024
|
Why Cassava Sciences Stock Is Sinking Today
- A former consultant to Cassava was indicted for alleged fraud related to NIH grants. Cassava received some federal funding related to these grants.
- 07/01/2024
|
Cassava Sciences Cooperates With DOJ, SEC On Controversial Alzheimer's Drug Investigation
- Cassava Sciences SAVA has engaged the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) amid ongoing investigations into the company and two senior employees.
- 07/01/2024
|
SAVA Stock Alert: Former Cassava Science Advisor Charged With Fraud
- Shares of Cassava Sciences (NASDAQ: SAVA ), which has an Alzheimer's drug candidate called simufilam, fell 35% on June 28 and another 13% over the weekend. This move in SAVA stock comes after a key science advisor was charged with defrauding the National Institutes of Health (NIH).
- 07/01/2024
|
Cassava Sciences shares fall after onetime advisor indicted on fraud charges
- Shares of biotech company Cassava Sciences Inc. plummeted on Friday after a federal grand jury indicted a onetime science advisor to Cassava and charged him with falsifying data to obtain millions of dollars in government funds — the latest drama for a company that has faced questions over its efforts to develop an experimental Alzheimer's disease drug.
- 06/28/2024
|
Cassava Sciences Shares Plunge on Indictment Against Former Advisor
- A federal indictment accuses a Cassava Sciences advisor of faking data to secure NIH grants. The company also faces shareholder suits.
- 06/28/2024
|
Cassava Sciences Issues Statement on Former Science Advisor
- AUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the U.S. National Institutes of Health (NIH). Hoau-Yan Wang was a tenured medical professor at a public university's medical school as well as a former paid science advisor to Cassava Sciences.
- 06/28/2024
|
Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich
- In 2024, the iShares Biotechnology ETF (NASDAQ: IBB ) is up just over 1.5%. If you're looking for steady, dividend-paying stocks, you can find a number of biotech stocks to buy from the holdings in this fund.
- 06/27/2024
|
2 Stocks Under $20 for Investors to Watch
- This week in Cheap Seats: Stocks Under $20 segment, we're taking a look at two stocks presenting an interesting buying opportunity: Cassava Sciences Inc (NASDAQ:SAVA) and Vale SA (NYSE:VALE).
- 06/12/2024
|
Cassava Sciences, Inc. (SAVA)'s Technical Outlook is Bright After Key Golden Cross
- After reaching an important support level, Cassava Sciences, Inc. (SAVA) could be a good stock pick from a technical perspective. SAVA recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
- 05/23/2024
|
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
- AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 million for the same period in 2023. Net cash used in operations was $19.1 million during the first quarter of 2024. Cash use for operations for the first half of 2024 is still expected to be $35 to $45 million, driven primarily by expenses for our clinical program in Alzheimer's disease.
- 05/10/2024
|
Annovis, Anavex, And Cassava Sciences: Trying To Box Oneself Out Of The Alzheimer's Box
- Recent results suggest that buntanetap, along with other treatments, does not significantly improve the condition of moderate Alzheimer's disease patients.
- 05/09/2024
|
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
- Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per Share Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per Share
- 05/08/2024
|
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
- AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA) (“Cassava Sciences” or the "Company") has been advised by NASDAQ that end-of-day (“EOD”) tomorrow May 2, 2024, will be the last and final trading day for SAVAW warrants on NASDAQ. After EOD May 2, the Company expects NASDAQ to no longer accept or execute any trade for SAVAW warrants.
- 05/01/2024
|
Stock Market Crash Warning: Don't Get Caught Holding These 3 Biotech Stocks
- Investing in the biotech sphere isn't for the faint of heart, and you should steer clear of the biotech stocks to avoid. That's because biotech stocks tend to experience wild swings in developments, such as clinical trial outcomes or drug approvals.
- 04/30/2024
|
Redemption Date Announced for Warrants
- AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (“Cassava Sciences” or the "Company") today announced that Monday, May 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on January 3, 2024 (the “Warrants”). Holders who exercise their Warrants will receive 1.5 shares of Cassava Sciences' common stock per Warrant, for an effective price of approximately $22.00 per share.
- 04/15/2024
|
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 04/01/2024
|
FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 04/01/2024
|
APRIL 2 FINAL DEADLINE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 03/31/2024
|
FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 03/30/2024
|
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
- NEW YORK , March 29, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the April 2, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in Cassava stock or options between August 18, 2022 and October 12, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
- 03/29/2024
|
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 03/29/2024
|
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 03/28/2024
|
ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA
- NEW YORK , March 27, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between August 18, 2022 and October 12, 2023, both dates inclusive (the "Class Period") of the important April 2, 2024 lead plaintiff deadline. SO WHAT: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 03/27/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
- NEW YORK , March 27, 2024 /PRNewswire/ -- (PRNEWSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). The class action, filed in the United States District Court for the Northern District of Illinois, and docketed under 24 -cv- 00977, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Cassava securities between August 18, 2022 and October 12, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
- 03/27/2024
|
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 03/27/2024
|
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 03/26/2024
|
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
- AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced the completion of another interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer's disease. A routine, scheduled meeting of a Data and Safety Monitoring Board (DSMB) recommended that both of Cassava Sciences' on-going Phase 3 studies continue as planned, without modification.
- 03/25/2024
|
APRIL 2 FINAL DEADLINE: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ:SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 03/25/2024
|
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / March 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc.. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
- 03/24/2024
|
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
- AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer's and Parkison's Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024.
- 03/04/2024
|
Exit Now! 3 Biotech Stocks to Sell in February 2024
- The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges.
- 02/21/2024
|
3 small-cap biotechs with potential breakthroughs in 2024
- There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.
- 02/06/2024
|
Is There Any Hope for Cassava Sciences Stock?
- Cassava Sciences stock is down due to questions about some of its research. A lot is riding on its late-stage clinical trials to produce favorable data.
- 02/03/2024
|
3 Biotech Stocks to Sell in January Before They Crash and Burn
- The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as companies' performance relies heavily on drug approvals.
- 01/25/2024
|
Portfolio Protection: 7 Risky Stocks to Drop Right Now
- With investors moving back towards a “risk-on” stance in recent months, you may think that risky stocks could lead to outsized rewards this year. Yet while more favorable economic and market conditions could extend the current bull market (which started in October) well into 2024, an improving macro picture may not be enough for stocks that have large company-specific risks.
- 01/12/2024
|
New SAVAW Warrants Are Trading After Cassava Sciences' Distribution
- In the biotechnology sector, Cassava Sciences (NADSAQ: SAVA ) remains one of the top clinical-stage companies that investors are watching. Over the past one year, SAVA stock is down by less than 20% but up nearly 9% for the past six months.
- 01/05/2024
|
Why Cassava Sciences Stock Zoomed 21% Higher This Week
- The biotech has declared a fresh dividend. The payout is rather atypical -- it's in the form of common stock warrants.
- 12/15/2023
|
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?
- Shares of pharmaceutical specialist Cassava Sciences (NASDAQ: SAVA ) soared earlier Tuesday before giving up most of the gains. Nevertheless, investor enthusiasm spiked over management's decision to issue a warrant distribution to support the ongoing Phase 3 clinical development of oral simulfilam, a promising therapeutic for patients of Alzheimer's disease.
- 12/12/2023
|
Why Cassava Sciences Stock Soared Today
- The biotech significantly modified its board of directors. Two of those incoming directors have extensive experience in the healthcare field; the other comes from the security sphere.
- 12/08/2023
|
Alzheimer's Disease Drug Development: Another Lost Year
- Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anavex's blarcamesine, Cyclo Therapeutics Trappsol Cyclo, Green Valley's GV-971, aromatherapy, and panax ginseng not only inhibit the formation of oxidants but scavenge them and reverse part of their damage.
- 12/05/2023
|
Cassava Sciences: Likely Potential Opportunity From Phase 3 Readout Next Year
- Cassava Sciences is a biotech company focused on developing treatments for Alzheimer's disease with its lead drug candidate, Simufilam. The company has faced allegations of data manipulation and misconduct, but no concrete evidence has been found to support these claims. The Phase 2 data for Simufilam showed potential cognitive benefits in patients with mild AD, but the results were inconsistent and had several limitations.
- 11/20/2023
|
7 High-Risk, High-Reward Stocks for the Extreme Contrarian
- Although the general concept of stock picks for contrarian investors may be universally appealing, when it comes to the most extreme examples, most investors should probably stay away. Basically, while the rewards for when the stars align can be enormously high, they rarely align.
- 11/14/2023
|
1 Big Red Flag to Fear When a Stock Is Down
- Stocks often lose much of their value as a result of controversies. Cassava Sciences is facing a raft of serious allegations from numerous parties.
- 10/31/2023
|
Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data
- Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidate, but outside research supports its apparent drug effect. Biomarkers show strong reductions in patients treated with simufilam, indicating potential efficacy in Alzheimer's disease. The reduction of NfL values over six months is similar to what led to the accelerated approval of Qalsody for ALS.
- 10/30/2023
|
7 Stocks That Are Heading for a Train Wreck
- One of the big slogans favored by CNBC pundit Jim Cramer is, “There's always a bull market somewhere.” I believe that's true.
- 10/19/2023
|
SAVA Stock Continues to Plunge on Misconduct Allegations
- Big problems appear to be getting worse for Cassava Sciences (NASDAQ: SAVA ). The clinical-stage biotech company is a former favorite among retail investors.
- 10/16/2023
|
SAVA Stock Alert: Cassava Sciences Addresses Leaked Report
- Cassava Sciences (NASDAQ: SAVA ) stock was hit hard after the market close yesterday following the publication of a Science article that released the details on a report published by the City University of New York (CUNY). The report accused Cassava collaborator and CUNY faculty member Hoau-Yan Wang of scientific misconduct, including image manipulation.
- 10/13/2023
|
Cassava Sciences slumps after leaked report claims 'egregious misconduct' over Alzheimer's drug
- Cassava Sciences Inc has denied data manipulation after a probe into conduct over its Alzheimer's drug research was leaked yesterday, sending its shares spiralling lower. Shares of Cassav were down nearly 21% on Friday morning at $13.97.
- 10/13/2023
|
Cassava shares plummet after investigation accuses researcher of ‘egregious misconduct'
- Shares of biotech company Cassava Sciences Inc. were slammed in extended trading Thursday, after the publication Science reported that an investigation accused a neuroscientist who often collaborated with the company of “long-standing and egregious misconduct” in data management and record keeping that raised serious questions about his research.
- 10/13/2023
|
Cassava Sciences slumps after leak claims “egregious misconduct”
- Cassava Sciences Inc has denied data manipulation after a probe into conduct over its Alzheimer's drug research was leaked yesterday, sending its shares into a spiral. The company's share price on NASDAQ dropped 29.30% on pre-market trades to a nadir of US$8.25 before settling by 20:00 local time, after closing at US$17.56 yesterday.
- 10/13/2023
|
Cassava Sciences: Unconvincing Open Label Studies, Upcoming Phase 3, Risky AD Bet
- The Alzheimer's Disease space is highly volatile, with stock prices reacting to positive or negative data from other companies in the sector. Cassava Sciences, Inc. experienced a correction after initial gains, highlighting the need for caution in the Alzheimer's space. Concerns were raised about the validity of Cassava's phase 2 trial, including participant bias, dropout bias, and the lack of a p-value.
- 10/11/2023
|
Why Shares of Cassava Sciences Soared This Week
- A rash of insider buying helped buoy the clinical-stage biotech's stock. Cassava said it had completed the enrollment of a phase 3 trial for an Alzheimer's disease drug.
- 10/06/2023
|
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
- AUSTIN, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer's disease dementia, today announced that Remi Barbier, President & Chief Executive Officer, is invited to present at the Jefferies Biotech CNS/Neuro Summit in New York on Wednesday, October 11, 2023 at 10:30am ET. A live webcast and archived replay will also be available.
- 10/05/2023
|
The 7 Best Meme Stocks to Buy Now: September 2023
- Given the horrendous performance of meme kings like AMC Entertainment (NYSE: AMC ) and GameStop (NYSE: GME ) lately, searching for the best meme stocks may be the last thing on your mind right now. In fact, considering GME's continued declines, and AMC's capitulation in recent weeks, you may think that the meme stock phenomenon has completely gone the way of the dodo.
- 09/14/2023
|
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
- AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer's disease dementia, today announced that it has been invited to present at the following investor conferences.
- 09/06/2023
|
Week Of 08/28 Notable Insider Buys
- Energy Transfer LP, Cassava Sciences, and PENN Entertainment Inc. were discussed in last week's insider trades update. CEO of Sirius XM Holdings Inc., Jennifer Witz, purchased 250,000 shares for over $1 million. Lyft, Inc. shares have risen nearly 20% since the introduction of new CEO David Risher in April, and insiders like the stock also.
- 09/05/2023
|
Week Of 08/21 Notable Insider Buys
- Energy Transfer LP CEO and Executive Vice President make significant insider purchases, with the CEO's YTD purchases totaling around $115 million. Cassava Sciences directors purchase shares amidst discussions of a potential short squeeze, despite the company's net losses and investigations. PENN Entertainment director buys shares following the company's $2 billion agreement with ESPN, despite a slight dip in share prices.
- 08/29/2023
|
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock
- Cassava Sciences (NASDAQ: SAVA ) stock jumped 5% overnight after director Richard Barry revealed he acquired shares on behalf of his trust. Barry paid $16.80 for each of the 1,905 shares on Aug. 21.
- 08/24/2023
|
Why These 3 Stocks Are the Worst Ways to Play Biotech Right Now
- The tech and growth segments of the market have been having a tremendous 2023 with one glaring exception. Traders have been choosing to avoid biotech stocks amid macroeconomic uncertainty around the sector.
- 07/13/2023
|
Cassava Sciences: Positive Data Continues To Derisk Ongoing Phase 3 Trials
- Cassava Sciences: Positive Data Continues To Derisk Ongoing Phase 3 Trials
- 07/09/2023
|
Cassava Sciences (SAVA) Stock Drops Despite Positive Trial Results
- Cassava Sciences (NASDAQ: SAVA ) stock is well in the red today despite announcing Phase 3 results for its Alzheimer's treatment. Indeed, SAVA stock is down more than 10% at the time of this writing on relatively lukewarm clinical trial news.
- 07/05/2023
|
Cassava Sciences: Why Market Skepticism Persists Despite Positive Findings On Simufilam
- Cassava Sciences' Alzheimer's drug, simufilam, reduced cognitive decline by 38% in a small study, but the results were not statistically significant, raising doubts about its efficacy. Despite a cash reserve of $187.5 million, Cassava's Q1 2023 net loss was $24.3 million, mainly due to increased patient enrollment costs for Phase 3 trials and other simufilam studies. Despite promising results, I maintain my "Strong Sell" recommendation for SAVA stock due to concerns about financial sustainability and the historically high failure rates of Alzheimer's drugs.
- 07/05/2023
|
Why Shares of Cassava Sciences Are Dropping Wednesday
- Simufilam slowed cognitive decline by 38% compared to a placebo after six months for patients with mild to moderate Alzheimer's disease. Cassava Sciences has been the target of shareholder lawsuits, short-seller reports, and government inquiries.
- 07/05/2023
|
Cassava Sciences to Present at the Jefferies Global Healthcare Conference
- AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City.
- 06/01/2023
|
Cassava (SAVA) Up on Progress With Alzheimers Disease Study
- Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.
- 05/30/2023
|
Why Shares of Cassava Sciences Jumped This Week
- The company has a small pipeline. Cassava also released data showing that Simufilam could be useful as an oncology drug.
- 05/12/2023
|
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?
- One of the stocks most in focus today for investors is Cassava Sciences (NASDAQ: SAVA ). Shares of SAVA stock have surged more than 15% as investors digest some promising news about the company's lead drug candidate.
- 05/09/2023
|
Buy Cassava Sciences For Imminent Data Readout
- Buy Cassava Sciences For Imminent Data Readout.
- 04/26/2023
|
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
- AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwright BioConnect Investor Conference in New York. In addition, management will be available for one-on-one meetings with institutional investors who are registered to attend this conference.
- 04/26/2023
|
Strong Small-Cap Insider Buys: Q1 2023
- Strong Small-Cap Insider Buys: Q1 2023.
- 04/26/2023
|
3 Short-Squeeze Stocks to Keep on Your Radar
- Short-squeezes have been making headlines in stock trading as an increasingly popular phenomenon. A short squeeze occurs when investors who have bet against a company's stock (by “shorting” it) are forced to buy back their shares to cut their losses.
- 03/09/2023
|
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
- Cassava Sciences (NASDAQ: SAVA ) stock rose 11% overnight after director Richard Barry said he bought shares worth $2.3 million. The company is working on an Alzheimer's drug called Simufilam.
- 03/09/2023
|
Cassava Sciences stock price outlook is bearish despite insider buy
- Cassava Sciences (NASDAQ: SAVA) stock price has been in a steep sell-off in the past few months as the enthusiasm of its pipeline wanes. Shares of the biopharmaceutical company were trading at $24.9 on Wednesday, ~51% below the highest level in 2022.
- 03/09/2023
|
Cassava Sciences: Open Label Study Data Unconvincing But Indicative Of Good Things
- Cassava Sciences' phase 2 data was from a nonrandomized trial, therefore unconvincing. However, it indicated drug efficacy quite strongly.
- 03/05/2023
|
Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a clinical-stage biotechnology firm that develops drugs for Alzheimer's disease (AD).
- 01/31/2023
|
Cassava Sciences' Data Once Again Misunderstood
- Cassava Sciences' Simufilam staved off cognitive decline in mild Alzheimer's disease. The market reacted negatively anyway.
- 01/27/2023
|
Cassava Sciences: Data For Mild Alzheimer's Disease Patients Provides Good Risk/Reward Profile
- Cassava Sciences released data for over 200 patients in an open-label trial at 12 months. The mild AD subgroup performed unprecedentedly.
- 01/26/2023
|
Why Is Cassava Sciences (SAVA) Stock Down 20% Today?
- One of the biggest decliners in today's market is Cassava Sciences (NASDAQ: SAVA ). Shares of SAVA stock declined more than 20% at today's trough on the company's announced mid-stage results for its Alzheimer's treatment.
- 01/24/2023
|
Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors
- Cassava disappointed Tuesday with midstage results for its oral Alzheimer's treatment and SAVA stock plummeted by a double-digit percentage. The post Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors appeared first on Investor's Business Daily.
- 01/24/2023
|
Is a Short Squeeze Coming in Cassava Sciences (SAVA) Stock?
- Amid surging interest in a wide swath of meme stocks today, retail investors are once again seeing traction in trading unpopular names. That said, other companies many may not necessarily associate with the meme trade are also surging.
- 01/11/2023
|
6 Favorite Biotech Bets For 2023
- Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's a six-pack of favorite biotech ideas for the coming year.
- 01/09/2023
|
Why Is Cassava Sciences (SAVA) Stock Up 10% Today?
- The completion of part of an important study is pushing Cassava Sciences (NASDAQ: SAVA ) stock up today. This clinical-stage biotech company has been volatile this month but has overall performed well.
- 12/07/2022
|
Cassava Sciences Stock's Bull Signal Has Never Been Wrong
- The shares of Cassava Sciences Inc (NASDAQ:SAVA) are down 3.5% at $32.17 this afternoon, after the company announced a $50 million registered direct stock offering on Friday.
- 11/21/2022
|
7 Stocks Rattled by Corporate Scandals and Shenanigans in 2022
- High inflation and soaring interest rates have been the main factor behind the double-digit stock downturn so far this year, but alongside these macro factors, many stocks have plunged due to more company-specific issues—for example, corporate scandals. These scandals run the gamut, both in the type of scandal and the severity of the scandal.
- 11/16/2022
|
Cassava Sciences stock pops after rival experiences setback in Alzheimer's research
- Yahoo Finance anchors Rachelle Akuffo, Seana Smith and Dave Briggs shares of Cassava moving higher on news that its rival Roche suffered a setback in its Alzheimer's drug research trial.
- 11/14/2022
|
Why Is Cassava Sciences (SAVA) Stock Up Today?
- In today's mixed session, there are plenty of stocks making big moves. Among the biggest movers in this afternoon's session is Cassava Sciences (NASDAQ: SAVA ).
- 11/14/2022
|
Cassava Sciences Has a Big Warning for SAVA Stock Short Sellers
- Shares of Cassava Sciences (NASDAQ: SAVA ) stock are in the spotlight following the company's third-quarter earnings and a stark warning to short sellers. During Q3, the company reported a net loss of $20.3 million, equivalent to an EPS loss of 51 cents per share.
- 11/07/2022
|
Trading Ideas On The Upcoming CTAD 2022 Conference
- The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.
- 11/02/2022
|
Why Is Cassava Sciences (SAVA) Stock Down 10% Today?
- Shares of Cassava Sciences (NASDAQ: SAVA ) declined by as much as 12% today but have since recovered to the $35 range, down about 4%. This was most likely attributed to the release of an article by Probes Reporter.
- 11/02/2022
|
Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?
- Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.
- 11/01/2022
|
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
- Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.
- 10/21/2022
|
SAVA Stock Alert: Cassava Sciences Extends Trial
- Shares of Cassava Sciences (NASDAQ: SAVA ) stock are in focus after the company announced that it would begin an open-label study on its investigational Alzheimer's disease ( AD ) drug, simufilam. The trial will be eligible for patients who complete either one of its ongoing Phase 3 studies.
- 10/13/2022
|
How High Can SAVA Stock Go Once the Controversy Clears?
- Sometimes, it's hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ: SAVA ).
- 09/30/2022
|
Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
- This is a highly speculative bet. There has been a constant litany of accusations of wrongdoing on the science.
- 09/29/2022
|
Should you buy Cassava Sciences as the stock continue to soar
- Retail interest in Cassava Sciences (NASDAQ:SAVA) remains far from over. The stock gained more than 6.7% on Wednesday, catapulting it to a 76% increase in value in a month.
- 09/28/2022
|
Why Is Cassava Sciences (SAVA) Stock Heating Up Today?
- Casava Sciences (NASDAQ: SAVA ) stock rose 5% overnight in sympathy with Biogen's (NASDAQ: BIIB ) successful clinical trial of an Alzheimer's drug called lecanemab. Lecanemab, developed with Eisai (OTCMKTS: ESALY ) of Japan, showed a decline in symptoms among 1,795 patients with early Alzheimer's, a brain disease impacting nearly one-third of Americans ages 85 and older.
- 09/28/2022
|
5 Investors Betting Big on Cassava (SAVA) Stock
- Shares of Cassava Sciences (NASDAQ: SAVA ) are down by over 15% following the previous day's gain of 35%. Yesterday, the Securities and Exchange Commission (SEC) announced that it had closed its case on Cassava.
- 09/23/2022
|
Cassava: High Risk Speculative Play With Enormous Potential
- Initiation of a phase 3 program open-label extension study using Simufilam for patients with Alzheimer's Disease is expected in 2nd half of 2022. An ongoing long-term open label study, initiated in March of 2020 is ongoing; Dosing completion is expected Q4 of 2022 and results from it are expected before end of 2022.
- 09/22/2022
|
The Huge Reason Cassava Sciences (SAVA) Stock Is Rocketing Higher
- Deleted: Despite a significant down day for the S&P 500, shares of Cassava Sciences (NASDAQ: SAVA ) closed higher by 35%. That's because the Securities and Exchange Commission (SEC) has closed its case on Cassava following the initiation of an investigation last November.
- 09/22/2022
|
Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Data
- The SEC reportedly cleared an investigation into Cassava Sciences, leading SAVA stock to hit a seven-month high Thursday. The post Cassava Skyrockets After SEC Clears It Of Tampering With Alzheimer's Data appeared first on Investor's Business Daily.
- 09/22/2022
|
The SEC Has Officially Cleared Cassava Sciences
- Cassava Sciences increased by over 10% intraday on positive SEC news. Cassava Sciences is up 26% in the last month while the market is down 7%.
- 09/22/2022
|
What Is Going on With Cassava (SAVA) Stock Today?
- Cassava Sciences (NASDAQ: SAVA ) stock rose nearly 30% on Sept. 20 as speculators bet on the company's efforts against Alzheimer's Disease.
- 09/21/2022
|
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
- AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held in New York.
- 09/08/2022
|
Cassava Sciences Looks As Good Of A Purchase As Ever
- Multiple insiders have purchased shares on the open market in the last month. The company has now released positive 100 patient 12-month data.
- 09/03/2022
|
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
- Cassava Sciences (NASDAQ: SAVA ) rose 9% overnight on reports director Richard Barry has invested $860,000 in the company's stock. The stock was due to open Aug. 26 at almost $30 per share, a market capitalization of almost $1.2 billion.
- 08/26/2022
|
These Are The Ten Best And Worst Performing Small-Cap Stocks In July 2022
- The small-cap Russell 2000 gained over 10% in July, compared to a jump of 9.1% for the S&P 500.
- 08/22/2022
|
Cassava Sciences, Blue Apron, and Revlon Stocks Exploded Out of the Gate Wednesday Morning
- These vastly different companies have one thing in common.
- 08/17/2022
|
Why Is Cassava Sciences (SAVA) Stock Up 20% Today?
- Cassava Sciences (NASDAQ: SAVA ) rose 20% in overnight trading after board member Sanford Robertson bought 100,000 shares. Chief financial officer Eric Schoen also bought shares.
- 08/17/2022
|
Stocks to watch: Apple, Digital World Acquistion Corp, Cassava Science, Canoo
- Yahoo Finance Live host Seana Smith breaks down the action surrounding trending stocks in after-hours trading, including how the Trump-tied SPAC is filing to delay earnings.
- 08/16/2022
|
Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
- After at least one year, 50 participants on simufilam experienced a 3.2 point improvement in ADAS-Cog scores whereas another group of 50 participants saw a .2 decline (on average). Acetylcholinesterase inhibitors produce a result between these two points in most individuals after one year.
- 08/11/2022
|
10 Stocks to Sell Before They Die
- This article is excerpted from Tom Yeung's Profit & Protection newsletter dated July 28, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.
- 07/29/2022
|
Cassava (SAVA) Stock Falls 30% on Report of Criminal Probe
- Cassava Biosciences (NASDAQ: SAVA ) stock is tumbling 30% in pre-market trading after Reuters reported today that the Justice Department has launched a criminal probe of the company. The news service cited two unnamed individuals as its sources for the article.
- 07/27/2022
|
US opens criminal probe into pharma company over potential Alzheimer's drug fraud: report
- A Texas-based pharmaceutical company is facing a criminal probe into allegations that it manipulated data in its studies on its Alzheimer's drug simuflam on Wednesday.
- 07/27/2022
|
Cassava's stock dives 24% after report citing alleged criminal probe of data from Alzheimer's drug trial
- Shares of Cassava Sciences Inc. SAVA, +0.14% plunged 24.2% in premarket trading on Wednesday after Reuters reported that the Justice Department is investigating whether the company manipulated clinical data for a still-investigational Alzheimer's disease drug, citing people familiar with the matter. Cassava put out a news release in December that said a scientific journal did not find evidence of manipulated data in a 2005 paper authored by the company's scientists after short sellers alleged data manipulation in some previously published research.
- 07/27/2022
|
Exclusive-Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say
- The U.S. Justice Department has opened a criminal investigation into Cassava Sciences Inc involving whether the biotech company manipulated research results for its experimental Alzheimer's drug, two people familiar with the inquiry said.
- 07/27/2022
|
7 Meme Stocks Trading at a Massive Discount Right Now
- 'Meme mania' has long since passed, but there may be an opportunity with these seven meme stocks trading at a discount right now. The post 7 Meme Stocks Trading at a Massive Discount Right Now appeared first on InvestorPlace.
- 07/24/2022
|
Cassava Sciences And Alzheimer's Disease: A Precipitious Path
- One probably should not invest in Cassava Sciences until all investigations are completed. Alternative mechanisms of action exist that better explain Cassava Sciences' trial results than the one offered by the company.
- 06/10/2022
|
5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List
- Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
- 05/24/2022
|
Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms
- Serious allegations have been made against Cassava by multiple sources, making SAVA stock far too risky for investors at this point. The post Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms appeared first on InvestorPlace.
- 04/29/2022
|
Take Full Advantage of Weakness in Cassava Sciences Stock
- Cassava could run back to $40 again. Should the company get a positive nod for its Alzheimer's treatment, it could see $140 again.
- 04/26/2022
|
Cassava Sciences Is a Worthwhile Bet to Consider
- FDA approval for Simufilam and successful trials of a new blood test to detect Alzheimer's disease could help propel SAVA stock back up. The post Cassava Sciences Is a Worthwhile Bet to Consider appeared first on InvestorPlace.
- 04/25/2022
|
The Crowd Has Wisely Soured on Cassava Sciences Stock
- As perceptions rise that its flagship drug candidate won't make it to market, steer clear of SAVA stock. The post The Crowd Has Wisely Soured on Cassava Sciences Stock appeared first on InvestorPlace.
- 04/20/2022
|
Fresh Crop of Concerns Surrounding Alzheimer's Drug Sinks SAVA
- The shares of Cassava Sciences Inc (NASDAQ:SAVA) are taking a drubbing this morning, last seen down 23.6% at $19.35, and set for their lowest open since January 2021.
- 04/19/2022
|
New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall
- Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after The New York Times detailed new allegations related to the studies of the company's experimental Alzheimer's therapy, simufilam. Among the latest concerns highlighted in the NYT article include a report.
- 04/19/2022
|
Why Is Cassava Sciences (SAVA) Stock Down Today?
- SAVA stock is tumbling after The New York Times reported that multiple experts are skeptical about Cassava's data and its main theory. The post Why Is Cassava Sciences (SAVA) Stock Down Today?
- 04/19/2022
|
Cassava Sciences Is Worth Considering After Hitting Its Latest Trough
- The company has no debt and is cash rich. If it receives FDA approval for its Simufilam drug, the SAVA stock price will catapult.
- 04/11/2022
|
3 Key Points To Remember About Cassava Sciences
- Cassava Sciences is trading near its 52 week lows.
- 04/07/2022
|
Why Is Cassava Sciences (SAVA) Stock Down Today?
- Cassava Sciences (SAVA) stock is falling on Tuesday as investors react to a recent fireside chat held by CEO Remi Barbier. The post Why Is Cassava Sciences (SAVA) Stock Down Today?
- 04/05/2022
|
Webcast Details for Cassava Sciences' Upcoming Fireside Chat
- – All Stakeholder Are Welcome to Listen by Webcast –
- 04/04/2022
|
Here's Why Cassava Sciences Stock Could Make a Comeback
- It helps to have plenty of cold, hard cash.
- 04/01/2022
|
Risk-on Biotech Investors Should Buy Cassava Sciences
- SAVA stock is volatile but worthwhile after opinion shifts in its favor. Remember, it has a blockbuster Alzheimer's drug nearing launch.
- 03/30/2022
|
Keep Risk in Mind With Cassava Sciences Stock, but Don't Dismiss Upside Potential
- If you can stomach the risk and have experience investing in clinical stage biotech plays, SAVA stock remains an interesting situation. After its recent weakness, you may find now to be the right time to initiate a position.
- 03/15/2022
|
Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know
- In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $37.31, marking a +0.54% move from the previous day.
- 03/04/2022
|
Cassava Sciences Is in a Bleak Midwinter Waiting for Spring and Better Days
- SAVA stock is driven by updates on clinical Phase 3 trials and lots of irrationality. Meanwhile, an FDA approval may take quite some time.
- 03/03/2022
|
Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know
- Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $42.51, moving +1.19% from the previous trading session.
- 02/25/2022
|
Why Cassava Sciences Is Still a High-Risk Play
- As it's not set in stone that Cassava Sciences will be able to bring simulfilam to market, you should approach SAVA stock cautiously. The post Why Cassava Sciences Is Still a High-Risk Play appeared first on InvestorPlace.
- 02/25/2022
|
Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know
- Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $49.22, moving +1.07% from the previous trading session.
- 02/15/2022
|
The FDA Deals Another Blow To Cassava Sciences' Bears
- The FDA Deals Another Blow To Cassava Sciences' Bears
- 02/11/2022
|
Benzinga's Daily Brief On Trending Tickers For Feb. 11, 2022: Cassava Sciences, Cleveland Cliffs, GameStop, and More
- Benzinga's “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks. The data on the trending tickers is compiled from a list of most-discussed tickers on the popular Reddit forum WallStreetBets.
- 02/11/2022
|
Here is where you can Cassava Sciences stock (SAVA): it is up 7% today
- After dropping since mid-November, the price of Cassava Sciences stock (SAVA) has bounced back and today it is up 7.78%. The current bullish outlook is a result of a denial by the FDA against Citizen Petitions Filed on Behalf of Short Selling Clients.
- 02/11/2022
|
Cassava Sciences, Inc. (SAVA) Gains But Lags Market: What You Should Know
- Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $47.12, moving +0.17% from the previous trading session.
- 02/08/2022
|
Does Cassava Sciences and Its Alzheimer's Drug Really Have What It Takes?
- Can Cassava Sciences' Simufilam drug really treat Alzheimer's? Who really knows.
- 02/08/2022
|
Keep an Eye on $60 as a Target Price for Cassava Sciences
- As long as you're using a moderate position size, it's fine to hold SAVA stock as it has a tendency to move fast and far from time to time. The post Keep an Eye on $60 as a Target Price for Cassava Sciences appeared first on InvestorPlace.
- 02/07/2022
|
Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
- Seeking Alpha longs have warned that increasing short positions in Cassava Sciences stock could result in a “short squeeze.”. For at least several days, comments on Seeking Alpha have disclosed that retail longs are receiving telephone calls from their brokers, asking if they are willing to loan their shares.
- 02/02/2022
|
Are Herron Therapeutics, Cassava Sciences Ripe for a Short Squeeze?
- As I pointed out in a previous discussion, short selling is not for the faint of heart and is probably best left to experienced traders. But there is an opportunity for investors to make money by keeping an eye on companies that could be subject to a short squeeze.
- 01/25/2022
|
Cassava Sciences Is an Exciting Roll-the-Dice Biotech Trade
- Take a wild ride -- but keep your position size small, please -- as SAVA stock could return to all-time highs or plummet to new depths soon. The post Cassava Sciences Is an Exciting Roll-the-Dice Biotech Trade appeared first on InvestorPlace.
- 01/24/2022
|
6 Top Biotech Ideas For 2022
- 6 Top Biotech Ideas For 2022
- 01/20/2022
|
Cassava Sciences Stock Is Still Risky but Has Plenty of Upside Potential
- Still, weighing risk against potential gains, the odds with SAVA stock may be on your side. If you are active in similar types of plays, consider it one to put on your watchlist.
- 01/18/2022
|
INmune Bio, The Biotech In My Stable For After Cassava Sciences
- Both Cassava Sciences and INmune Bio have brought impressive results on neuroinflammation and neurodegeneration. I expect INmune Bio's XPro to yield impressive results in its phase 2 trials like Cassava Sciences' simufilam did.
- 01/17/2022
|
7 High Risk Stocks That Are Worth The Volatile Vibes
- These seven high risk stocks made wild moves in 2021, but still have the potential to rocket higher. All are full of both risk and reward.
- 01/10/2022
|
Where Will Cassava Sciences Be in 1 Year?
- It could be a make-or-break year for the clinical-stage biotech.
- 01/07/2022
|
Cassava Sciences, Inc. - The Short Squeeze Has Started
- I provide and compare historical data from the GameStop and AMC short squeezes that occurred last year to Cassava Sciences. The short squeeze for Cassava Sciences has already started – as was the case for GameStop, recall that the increase in price-per-share for GameStop occurred over 12 trading days.
- 01/06/2022
|
Cassava Sciences: Likelihood Of FDA Success Implies 11x Upside
- The market is pricing in an approximately 6% chance of FDA approval for Cassava Sciences' Alzheimer's small molecule pill, Simufilam. The distribution of 147,000 Simufilam to more than 250 Alzheimer's patients in at least 16 investigator sites shows zero drug-related serious adverse events vs. 69% occurrence of ARIA with Biogen.
- 01/03/2022
|
Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?
- Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
- 12/31/2021
|
Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
- I do not believe that a short position in Cassava Sciences stock is rational.
- 12/30/2021
|
7 of the Best Meme Stocks for 2022 to Buy Now
- Although the meme stocks phenomenon is sagging in popularity, these seven current and/or former Reddit favorites could make another "to the moon" move or two in 2022. The post 7 of the Best Meme Stocks for 2022 to Buy Now appeared first on InvestorPlace.
- 12/30/2021
|
5 Stocks I'd Sell Right Now
- These could be some of the worst-performing and riskiest investments in 2022.
- 12/29/2021
|
Best Health Care Stocks To Buy Now? 3 For Your 2022 Watchlist
- Health care stocks worth knowing as the Omicron Covid-19 variant sweeps the globe.
- 12/28/2021
|
SAVA Stock Alert: What Is Going on With Red-Hot Cassava Sciences Today?
- Biotech company Cassava saw a big jump today on positive news related to its Alzheimer's disease treatment. Keep an eye on SAVA stock.
- 12/21/2021
|
Cassava Sciences Stock: Here We Go Again
- While the interim data looks fantastic, and some are pushing for early approval of the drug by the FDA, some questions remain surrounding the academic integrity of the work.
- 12/21/2021
|
Science Journal Finds No Evidence To Data Manipulation By Cassava Sciences' In 2005 Publication
- Cassava Sciences Inc (NASDAQ: SAVA) has been informed by the Neuroscience journal that there is no evidence to support claims of data manipulation in a 2005 paper authored by the Company and its scientific collaborators. "Another science journal has cleared us of allegations," said Remi Barbier, President & CEO.
- 12/21/2021
|
Top Penny Stocks To Buy? 3 Former Stocks Under $5 To Watch Now
- Are these former penny stocks on your list to buy right now or is the rally over? The post Top Penny Stocks To Buy?
- 12/21/2021
|
SAVA Stock: The Social Media Chatter That Has Cassava Sciences Trending Today
- Cassava Sciences (SAVA) stock is getting some extra attention today from traders on social media and we've got all the details. The post SAVA Stock: The Social Media Chatter That Has Cassava Sciences Trending Today appeared first on InvestorPlace.
- 12/21/2021
|
Cassava Stock Surges as Social Media Buzz Intensifies
- The shares of Cassava Sciences Inc (NASDAQ:SAVA) are surging before the bell, last seen up 33.6% at $49.13, as the heavily shorted stock gains popularity on social media this morning.
- 12/21/2021
|
Cassava Sciences Stock (SAVA): Why The Price Surged
- The shares of Cassava Sciences, Inc. (NASDAQ: SAVA) were halted this morning. This is why it happened.
- 12/21/2021
|
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
- These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. The post 7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts appeared first on InvestorPlace.
- 12/07/2021
|
Interview With Cassava Sciences' CEO Remi Barbier - Data Integrity, Elon Musk, And The Haters
- We have a wide-ranging phone interview with Cassava Sciences' CEO Remi Barbier. He addresses crazy accusations and data safeguards.
- 12/06/2021
|
Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
- Cassava Sciences has been one of 2021's best stocks. We can learn some things from Cassava to help us find the next great biotech or growth & innovation stock.
- 12/01/2021
|
Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?
- Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
- 11/26/2021
|
Cassava Sciences Just Returned to the Buy Zone
- There's no need to panic about SAVA stock, as Cassava Sciences just launched an important study focused on treating Alzheimer's disease. The post Cassava Sciences Just Returned to the Buy Zone appeared first on InvestorPlace.
- 11/22/2021
|
Will Cassava Sciences Stock Continue To See Lower Levels?
- The stock price of Cassava Sciences plunged 23% yesterday after a report that the U.S. SEC is investigating the company over allegations of data manipulation for its experimental Alzheimer's treatment - Simufilam. [1] SAVA stock saw a large fall in September following a citizen petition filed to.
- 11/19/2021
|
Cassava Sciences Kickstarts Second Late-Stage Alzheimer's Trial With Simufilam
- Cassava Sciences Inc (NASDAQ: SAVA) has initiated a second Phase 3 study of simufilam in patients with Alzheimer's disease. The second Phase 3 study is designed to evaluate the safety and efficacy of oral simufilam 100 mg and 50 mg over 78 weeks over 78 weeks in approximately 1,000 patients.
- 11/18/2021
|
Is An Accelerated Approval Likely For Cassava Sciences?
- Cassava Sciences is a company with a promising Alzheimer's Drug candidate. The FDA has a process called accelerated approval that allows for drugs to be approved for use before the finishing of drug trials.
- 11/18/2021
|
Cassava (SAVA) Down on Report of SEC Investigation Into AD Program
- Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.
- 11/18/2021
|
3 Biotech Stocks That Have More Than Tripled so far This Year
- But can they keep up the momentum?
- 11/18/2021
|
See Why Cassava Sciences Shares Are Falling On Wednesday?
- The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences Inc (NASDAQ: SAVA) manipulated data key to its case for its experimental Alzheimer's drug simufilam. The report comes just two days after Cassava, in an SEC filing, revealed that “certain government agencies” had asked the Company for documentation.
- 11/17/2021
|
Why Cassava Sciences Is Sliding Lower Today
- Allegations of data manipulation that hammered the company -- and its stock price -- this summer won't be easily forgotten.
- 11/17/2021
|
Today's Hot Penny Stocks: What's Moving ZSAN, AVGR and CEI Higher Wednesday?
- Today's hot penny stocks are catching the eyes of investors and we're diving into everything investors need to know about them on Wednesday! The post Today's Hot Penny Stocks: What's Moving ZSAN, AVGR and CEI Higher Wednesday?
- 11/17/2021
|
7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside
- Here are seven of the top short-squeeze stocks investors may want to keep their eye on, as retail investors lay and wait for the next squeeze. The post 7 Short-Squeeze Stocks Loaded With High-Risk, High-Reward Upside appeared first on InvestorPlace.
- 11/11/2021
|
Biogen Vs. Cassava Sciences Stock: Which Is The Better Buy?
- Neurological diseases including Alzheimer's are a huge unmet need that BIIB and SAVA are working on solutions for. BIIB's diversification, low sentiment, and profitability make it more suitable to a wider audience of investors.
- 11/11/2021
|
Cassava Sciences: Cash Is King
- The company's Q3 earnings "missed" expectations which is laughable. Cassava is increasing spending to get its phase 3 trials off the ground.
- 11/10/2021
|
An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why
- An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why
- 11/10/2021
|
Cassava Sciences Stock: Top Contender For A Continued Short Squeeze
- Cassava Sciences Stock: Top Contender For A Continued Short Squeeze
- 11/10/2021
|
Cassava Sciences Needs Time and Data to Prove Itself Before You Buy
- Even as SAVA stock whipsaws in both directions, Cassava's commitment to treating Alzheimer's disease remains as firm and steady as ever. The post Cassava Sciences Needs Time and Data to Prove Itself Before You Buy appeared first on InvestorPlace.
- 11/09/2021
|
Cassava Is a Sell After Accusations of Data Manipulation
- After Cassava was accused of multiple improprieties for its star Simufilam drug, investors should sell the vast majority of their SAVA stock. The post Cassava Is a Sell After Accusations of Data Manipulation appeared first on InvestorPlace.
- 11/09/2021
|
Cassava Sciences' Hypothesis Raises Doubts
- Central to Cassava's hypothesis requires amyloid beta-42 to induce an altered conformation of structural protein filamin A and that sumifilam restores altered filmin A back to its native state. Researchers have demonstrated that mutations that cause familial AD, amyloid beta-40, and -42 production is more likely to be reduced or abolished due to decreased enzymatic activity of gamma-secretase.
- 11/08/2021
|
4 Top Biotech Stocks To Watch This Week
- Check out these biotech stocks that could prove to be valuable additions to your portfolio.
- 11/08/2021
|
Short Squeeze Stocks: PROG, SAVA and 3 Others Experts Think Are Ready to Pop
- Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.
- 11/08/2021
|
Cassava Sciences: A Close Look
- On Nov 4, Cassava Sciences issued a PR which headline reads, 'Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences' And the sub-heading: It states, "No evidence of data manipulation was found for Western blot data."
- 11/06/2021
|
Stocks Heading Into Holiday Season With Record Highs
- Stocks continued their run of near daily record highs heading into November, as investors digested a slew of economic updates and earnings reports.
- 11/05/2021
|
Alzheimer's - Cassava Sciences, Cortexyme Or Anavex: Who Will Come On Top?
- Cassava Sciences' Simufilam is now seen as the best hope to treat all patients in Alzheimer's disease after disappointment in Cortexyme's data.
- 11/05/2021
|
Cassava Sciences (SAVA) Stock: Why The Price Surged Today
- The stock price of Cassava Sciences Inc (NASDAQ: SAVA) surged 48.96% today. This is why it happened.
- 11/04/2021
|
Why Did Cassava Sciences Stock Jump 49% Today?
- Journal of Neuroscience has informed Cassava Sciences Inc (NASDAQ: SAVA) that there is no evidence of data manipulation in an article published in July 2012 describing a new approach to treating Alzheimer's disease. The peer-reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences and is foundational to simufilam, the Company's lead Alzheimer's candidate.
- 11/04/2021
|
Cassava Sciences Stock Surges on Alzheimer's Article Update
- Cassava Sciences Inc (NASDAQ:SAVA) is soaring today, up 46.1% to trade at $82.80 at last glance, after the company said the Journal of Neuroscience found no evidence of data manipulation in its 2012 article describing a new approach to treating Alzheimer's.
- 11/04/2021
|
Cassava Sciences: Major Hit To The Bears
- No evidence of data manipulation.
- 11/04/2021
|
Why Cassava Sciences Shares Are Rising
- Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher after a review by the Journal of Neuroscience showed there is no evidence of data manipulation in a 2012 company technical paper. "I've never doubted the integrity of our people or science," said Remi Barbier, President & CEO.
- 11/04/2021
|
SAVA Stock Alert: Why Cassava Sciences Is Rocketing 50% Higher Today
- Cassava Sciences just got good news. SAVA stock is soaring as the company celebrates the end of its manipulated data accusations.
- 11/04/2021
|
Is it too risky to buy Cassava Sciences as Quintessential says the stock is worthless?
- On Wednesday, Cassava Sciences Inc. (NASDAQ:SAVA) shares plunged more than 7% after Quintessential Capital management released a report saying the stock is worthless. The firm called for shorts to swoop in claiming its Alzheimer's drug Simufilam seems to be based on forged research.
- 11/03/2021
|
Cassava Sciences Is on a Bumpy Road to Multibagger Status
- Based on analyst estimates for the next ten years, SAVA stock could be worth three times more if its Alzheimer's drug succeeds. The post Cassava Sciences Is on a Bumpy Road to Multibagger Status appeared first on InvestorPlace.
- 11/03/2021
|
Cassava Sciences (SAVA) to Post Q3 Earnings: What's in Store?
- Investors will watch for updates on its lead candidate, sumifilam, for Alzheimer's disease in Cassava's (SAVA) Q3 earnings call.
- 11/01/2021
|
Cassava Sciences Stock: Massive Potential Marred By Controversy
- Cassava Sciences, Inc. is a pre-revenue biotechnology company. The company specializes in neurodegenerative diseases, such as Alzheimer's disease.
- 11/01/2021
|
Cassava Sciences' Stock Remains an Enigma
- Cassava Sciences has lost 26% for the month through Oct. 27. Entering October, SAVA stock looked to go on a big run.
- 11/01/2021
|
Buy SAVA Stock on Dips as its Phase 3 Trial Moves Along
- There's no way to mitigate its high risk nature completely. But if you're bullish on Simulfilam?
- 10/29/2021
|
Cassava Sciences: Welcome To The Casino
- There is a lot of hope with this one for those suffering from Alzheimer's.
- 10/25/2021
|
3 Biotech Stocks That Are Ridiculously Overpriced
- They've risen too far, too quickly.
- 10/20/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)
- New York, New York--(Newsfile Corp. - October 19, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20539&from=5
- 10/19/2021
|
SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - October 19, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20530&wire=5
- 10/19/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - October 19, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20524&from=5
- 10/19/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA
- New York, New York--(Newsfile Corp. - October 18, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers. The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that...
- 10/18/2021
|
SHAREHOLDER ALERT: SAVA WDH HNST: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / October 18, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
- 10/18/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - October 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 10/18/2021
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of KPLT, SAVA and SPPI
- NEW YORK, NY / ACCESSWIRE / October 17, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
- 10/17/2021
|
Rosen, Top Ranked Investor Counsel, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA
- New York, New York--(Newsfile Corp. - October 16, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out of...
- 10/16/2021
|
Cassava Update
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 16, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal...
- 10/16/2021
|
(SAVA) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Cassava Class Action Lawsuit
- SAN DIEGO, Oct. 16, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). The class action is on behalf of shareholders who purchased Generac common stock between September 14, 2020 and August 27, 2021.
- 10/16/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA
- NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers. The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Cassava securities between September 14, 2020 and August 27, 2021, inclusive (the "Class Period").
- 10/15/2021
|
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - October 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
- 10/15/2021
|
LAWSUIT FILED - CASSAVA SCIENCES Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information
- Boston, Massachusetts--(Newsfile Corp. - October 15, 2021) - Block & Leviton announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for potential securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/sava.What is this all about?Earlier today the National Institute of Health "NIH" indicated it is aware...
- 10/15/2021
|
Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - October 15, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
- 10/15/2021
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SAVA, SAM and APPH
- NEW YORK, NY / ACCESSWIRE / October 15, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
- 10/15/2021
|
Cassava Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 14, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Cassava stock or options...
- 10/14/2021
|
CLASS ACTION UPDATE for KPLT, SAVA and HYZN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / October 14, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
- 10/14/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - October 14, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
- 10/14/2021
|
SAVA LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Cassava Sciences, Inc. Shareholders
- New York, New York--(Newsfile Corp. - October 14, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=20435&from=5
- 10/14/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)
- New York, New York--(Newsfile Corp. - October 13, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20420&from=5
- 10/13/2021
|
Lawsuits Filed Against SAVA, SPPI and APPH - Jakubowitz Law Pursues Shareholders Claims
- NEW YORK, NY / ACCESSWIRE / October 13, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.
- 10/13/2021
|
CASSAVA SCIENCES, INC. (SAVA) SHAREHOLDER LAWSUIT DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - October 13, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the...
- 10/13/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences (SAVA) Investors with $250K+ Losses to Contact Firm's Attorneys Now, Deadline Approaching in Securities Fraud Lawsuit
- San Francisco, California--(Newsfile Corp. - October 13, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concer
- 10/13/2021
|
SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
- LOS ANGELES, Oct. 13, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Class Period: September 14, 2020 and August 27, 2021 Lead Plaintiff Deadline: October 26, 2021 If you wish to serve as lead plaintiff of the Cassava lawsuit, you can submit your contact information at https://www.glancylaw.com/cases/cassava-sciences-inc/.
- 10/13/2021
|
SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - October 13, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20389&wire=5
- 10/13/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - October 13, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20378&from=5
- 10/13/2021
|
Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. (SAVA)
- Radnor, Pennsylvania--(Newsfile Corp. - October 12, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021, inclusive (the "Class Period").CLICK HERE TO SUBMIT YOUR CASSAVA LOSSESLEAD PLAINTIFF DEADLINE: October 26, 2021CLASS PERIOD: ...
- 10/12/2021
|
Cassava Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 12, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Cassava stock or...
- 10/12/2021
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SAVA, HYRE and APPH
- NEW YORK, NY / ACCESSWIRE / October 12, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
- 10/12/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - October 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
- 10/12/2021
|
CASSAVA SCIENCES, INC. (SAVA) SHAREHOLDER LAWSUIT DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - October 12, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
- 10/12/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - October 12, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 10/12/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)
- New York, New York--(Newsfile Corp. - October 12, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20329&from=5
- 10/12/2021
|
SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - October 11, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20315&wire=5
- 10/11/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Cassava Sciences (SAVA) Investors of Pending Securities Fraud Lawsuit, Encourages Investors with $250K+ Losses to Contact Firm's Attorneys Now
- San Francisco, California--(Newsfile Corp. - October 11, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now. Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements...
- 10/11/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - October 11, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20299&from=5.
- 10/11/2021
|
Cassava Sciences: Fine Trading Stock, Terrible Investment
- SAVA stock has fallen sharply in recent weeks. However, it's still a rather expensive bet on a controversial drug heading into Phase 3 trials.
- 10/11/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - October 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 10/11/2021
|
Important Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. Investors of Securities Fraud Class Action Lawsuit
- RADNOR, Pa., Oct. 10, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors of Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Cassava securities between September 14, 2020 and August 27, 2021 , inclusive (the "Class Period").
- 10/10/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA
- New York, New York--(Newsfile Corp. - October 9, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers. The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
- 10/09/2021
|
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important October 26 Deadline in Securities Class Action – SAVA
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the “Class Period”), of the important October 26, 2021 lead plaintiff deadline. SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem
- 10/09/2021
|
Cassava Update
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 9, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.If you suffered losses exceeding $50,000 investing in Cassava stock or options between...
- 10/09/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - October 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
- 10/08/2021
|
CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. Shareholders of Securities Fraud Class Action Lawsuit
- Radnor, Pennsylvania--(Newsfile Corp. - October 8, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Cassava securities between September 14, 2020 and August 27, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Cassava securities during the Class Period may, no later...
- 10/08/2021
|
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - October 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
- 10/07/2021
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PHG, SESN and SAVA
- NEW YORK, NY / ACCESSWIRE / October 7, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
- 10/07/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA
- NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers. The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Cassava securities between September 14, 2020 and August 27, 2021, inclusive (the "Class Period").
- 10/07/2021
|
Cassava Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 7, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
- 10/07/2021
|
HAGENS BERMAN Encourages Cassava Sciences (SAVA) Investors with $250K+ Losses to Contact Firm's Attorneys Now, Securities Fraud Class Action Pending
- San Francisco, California--(Newsfile Corp. - October 7, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concern
- 10/07/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - October 7, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20216&from=5
- 10/07/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)
- New York, New York--(Newsfile Corp. - October 7, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20199&from=5
- 10/07/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - October 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 10/06/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - October 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
- 10/06/2021
|
SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - October 6, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20179&wire=5
- 10/06/2021
|
Cassava Sciences Starts Late-Stage Simufilam Study In Alzheimer's Patients
- Cassava Sciences Inc (NASDAQ: SAVA) initiated an initial Phase 3 efficacy study of simufilam, an investigational drug for patients with Alzheimer's disease. A second Phase 3 efficacy study of simufilam in Alzheimer's disease is expected to begin by year-end.
- 10/06/2021
|
CASSAVA SCIENCES, INC. (SAVA) SHAREHOLDER LAWSUIT DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - October 6, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
- 10/06/2021
|
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer's Disease
- AUSTIN, Texas, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, announced today it has initiated an initial Phase 3 efficacy study of simufilam, the Company's investigational drug for patients with Alzheimer's disease. A second Phase 3 efficacy study of simufilam in Alzheimer's disease is expected to begin by year end.
- 10/06/2021
|
Cassava Sciences Stock Could Explode as FDA Approval Is a Real Possibility
- SAVA stock is volatile but worthwhile as its Alzheimer's drug inches closer to commercialization. Risk tolerance is needed, but likely smart The post Cassava Sciences Stock Could Explode as FDA Approval Is a Real Possibility appeared first on InvestorPlace.
- 10/06/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - October 6, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20159&from=5
- 10/06/2021
|
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA
- NEW YORK, Oct. 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline. SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 10/05/2021
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PHG, LIVE and SAVA
- NEW YORK, NY / ACCESSWIRE / October 5, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
- 10/05/2021
|
Cassava Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 5, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or options...
- 10/05/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - October 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 10/05/2021
|
HAGENS BERMAN Notifies Cassava Sciences (SAVA) Investors of October Deadline in Securities Class Action, Encourages Investors with $250K+ Losses to Contact Firm's Attorneys Now
- San Francisco, California--(Newsfile Corp. - October 5, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concerning...
- 10/05/2021
|
Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
- 10/05/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)
- New York, New York--(Newsfile Corp. - October 5, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20126&from=5
- 10/05/2021
|
SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - October 4, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20114&wire=5
- 10/04/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - October 4, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20110&from=5
- 10/04/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - October 4, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
- 10/04/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - October 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 10/04/2021
|
Use Cassava Sciences Stock Weakness as Buy Opportunity Ahead of Phase 3
- If Cassava Sciences' Alzheimer drug can continue to produce solid results, it could see FDA approval before the end of 2022. SAVA stock may not be oversold for long.
- 10/04/2021
|
What to Make of Cassava Sciences' Late September Rally
- Cassava Sciences gained 50% in the second half of September. Now the question is, can SAVA stock keep up momentum in October?
- 10/04/2021
|
Cassava Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 3, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or options...
- 10/03/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA
- New York, New York--(Newsfile Corp. - October 2, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers. The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
- 10/02/2021
|
Investor Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. - SAVA
- Radnor, Pennsylvania--(Newsfile Corp. - October 2, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors of Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Cassava securities during the Class Period may, no...
- 10/02/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadline - SAVA
- New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers. The class action, filed in the United States District Court for the Western District of Texas, and docketed under 21-cv-00856, is on behalf of a class consisting of all persons and entities other than Defendants that...
- 10/01/2021
|
HAGENS BERMAN Alerts Cassava Sciences (SAVA) Investors to Approaching Deadline in Securities Class Action, Encourages Investors with $250K+ Losses to Contact Firm's Attorneys Now
- San Francisco, California--(Newsfile Corp. - October 1, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now. Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVAContact An Attorney Now: SAVA@hbsslaw.com844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concerning Casava's Alzh
- 10/01/2021
|
Cassava Stock Has Reached a Positive Turning Point
- Cassava is rebounding and SAVA stock may rally back to its old highs as it fends off a short-selling attack. The post Cassava Stock Has Reached a Positive Turning Point appeared first on InvestorPlace.
- 10/01/2021
|
The Good News Is Piling Up for Cassava Stock
- Recent news indicates that the FDA is going to reject a petition against Cassava, helping to make SAVA stock very attractive. The post The Good News Is Piling Up for Cassava Stock appeared first on InvestorPlace.
- 10/01/2021
|
SAVA LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Cassava Sciences, Inc. Shareholders
- New York, New York--(Newsfile Corp. - October 1, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=20034&from=5
- 10/01/2021
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PHG, ATIP and SAVA
- NEW YORK, NY / ACCESSWIRE / September 30, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
- 09/30/2021
|
Cassava Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 30, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
- 09/30/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)
- New York, New York--(Newsfile Corp. - September 30, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=20021&from=5
- 09/30/2021
|
SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - September 30, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=20016&wire=5
- 09/30/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - September 30, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=20003&from=5
- 09/30/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - September 30, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information go to:https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19994&wire=5or...
- 09/30/2021
|
Pomerantz Law Firm Announces the Filing of a Class Action Against Cassava Sciences, Inc. and Certain Officers - SAVA
- NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers.
- 09/29/2021
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VIEW, SAVA and HNST
- NEW YORK, NY / ACCESSWIRE / September 29, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.
- 09/29/2021
|
Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - September 29, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
- 09/29/2021
|
Cassava Sciences' Simufilam Could Be Approved Before The End Of 2022
- Cassava Sciences Alzheimer's treatment has proven to not only slow down but also reverse cognition degeneration in Alzheimer's patients leaving the door open for early approval. Concerns existed on a possible placebo effect but recently presented 12-month data put those concerns aside and furthermore opened the door for FDA fast track approval or breakthrough designation.
- 09/29/2021
|
SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - September 29, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19963&wire=5
- 09/29/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - September 28, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19949&from=5
- 09/28/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - September 28, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more...
- 09/28/2021
|
SAVA INVESTOR LAWSUIT DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - September 28, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
- 09/28/2021
|
SAVA EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of Cassava Sciences, Inc.
- RADNOR, Pa., Sept. 28, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces to investors that a securities fraud class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021 , inclusive (the "Class Period").
- 09/28/2021
|
SAVA INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Cassava Sciences (SAVA) Investors with $250K+ Losses to Contact Firm's Attorneys Now, Securities Fraud Lawsuit Filed
- San Francisco, California--(Newsfile Corp. - September 28, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now. Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVAContact An Attorney Now: SAVA@hbsslaw.com844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concerning Casava's Alz
- 09/28/2021
|
What's Happening With Cassava Sciences Stock?
- Last month we discussed that Cassava Sciences stock, based on historical performance, is likely to see lower levels after it plunged 24% in a week following a citizen petition filed to halt the trials for Simufilam - Cassava's promising candidate for the treatment of Alzheimer's disease.
- 09/28/2021
|
Is Cassava Sciences Back in the Game?
- There's nothing spectacular about the latest results for the company's flagship drug.
- 09/28/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - September 27, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: September 14, 2020 and August 27, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19907&from=5
- 09/27/2021
|
NATIONALLY RANKED ROSEN LAW FIRM Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA
- New York, New York--(Newsfile Corp. - September 27, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out...
- 09/27/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - September 27, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 09/27/2021
|
Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - September 27, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
- 09/27/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - September 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 09/26/2021
|
(SAVA) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel Regarding Leading Cassava Sciences Class Action Lawsuit
- SAN DIEGO, Sept. 25, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that purchasers of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, have until October 26, 2021, to file a lead plaintiff motion.
- 09/25/2021
|
Cassava Update
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 25, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or options...
- 09/25/2021
|
LAWSUITS FILED AGAINST OTLY, LIVE and SAVA - Jakubowitz Law Pursues Shareholders Claims
- NEW YORK, NY / ACCESSWIRE / September 24, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court.
- 09/24/2021
|
Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - September 24, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
- 09/24/2021
|
SAVA LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Cassava Sciences, Inc. Shareholders
- New York, New York--(Newsfile Corp. - September 24, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=19844&from=5
- 09/24/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)
- New York, New York--(Newsfile Corp. - September 23, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE: https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=19828&from=5
- 09/23/2021
|
ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA
- NEW YORK, Sept. 23, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.
- 09/23/2021
|
Cassava Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 23, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
- 09/23/2021
|
SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - September 23, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19811&wire=5
- 09/23/2021
|
Why Shares of Cassava Sciences Rose 15% Today
- Additional data is promising. But will investors trust it?
- 09/23/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences (SAVA) Investors with Losses in Excess of $250,000 to Contact Firm's Attorneys Now, Securities Fraud Class Action Filed
- San Francisco, California--(Newsfile Corp. - September 23, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions conc
- 09/23/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - September 23, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19800&from=5
- 09/23/2021
|
SAVA INVESTOR LAWSUIT DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.
- NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period").
- 09/23/2021
|
Cassava (SAVA) Posts Top-Line Data from AD Study on Simufilam
- Cassava (SAVA) reports top-line data from an interim analysis of the on-going study evaluating simufilam in patients with mild-to-moderate Alzheimer's disease.
- 09/23/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - September 23, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 09/23/2021
|
MRM Stock: The Hair Salon Deal That has Holistic Healthcare Play Medirom All Lathered Up Today
- Medirom Healthcare Technologies (MRM) stock is rocketing higher on Thursday following news of a major deal for the company. The post MRM Stock: The Hair Salon Deal That has Holistic Healthcare Play Medirom All Lathered Up Today appeared first on InvestorPlace.
- 09/23/2021
|
Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
- Radnor, Pennsylvania--(Newsfile Corp. - September 22, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Cassava securities during the Class Period may, no later...
- 09/22/2021
|
SAVA: Berman Tabacco Alerts Investors with Losses Over $200,000 in Cassava Sciences, Inc. of Approaching Lead Plaintiff Deadline
- Boston, Massachusetts--(Newsfile Corp. - September 22, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24,...
- 09/22/2021
|
Should you buy SAVA stock in Q4 2021 amid positive Simufilam trial data?
- On Wednesday, Cassava Sciences Inc. (NASDAQ:SAVA) shares swang to a net intraday loss of about 3.52%, as of this writing, despite spiking more than 21% in the morning. The stock surged after the company posted top-line data on a pre-planned interim analysis of an ongoing open-label study with its drug label Simufilam in patients with […] The post Should you buy SAVA stock in Q4 2021 amid positive Simufilam trial data?
- 09/22/2021
|
SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?
- Today, Cassava Sciences initially soared on the announcement of some positive preliminary data, before SAVA stock began selling off. The post SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?
- 09/22/2021
|
Cassava Sciences' Simufilam Data Shows Improved Cognition In Alzheimer's Disease
- Cassava Sciences Inc (NASDAQ: SAVA) has announced top-line data from a pre-planned interim analysis of an ongoing open-label study of simufilam in mild-to-moderate Alzheimer's disease. Related Content: Cassava CEO Goes Offensive Over Simufilam Data Allegations.
- 09/22/2021
|
Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer's Disease
- AUSTIN, Texas, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced top-line clinical data today from a pre-planned interim analysis of an on-going open-label study with its drug candidate simufilam in patients with mild-to-moderate Alzheimer's disease.
- 09/22/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - September 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 09/21/2021
|
Cassava Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 21, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or options...
- 09/21/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
- New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Cassava and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about...
- 09/21/2021
|
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important October 26 Deadline in Securities Class Action - SAVA
- New York, New York--(Newsfile Corp. - September 21, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out of...
- 09/21/2021
|
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Cassava Sciences, Inc. (SAVA) Investors and Encourages Investors to Contact the Firm Before October 26, 2021
- NEW YORK--(BUSINESS WIRE)---- $SAVA--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Western District of Texas on behalf of those who acquired Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities from September 14, 2020 through August 27, 2021, inclusive (the “Class Period”). Investors have until October 26, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Cassava is a
- 09/21/2021
|
Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - September 21, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period").If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please contact...
- 09/21/2021
|
Cassava Sciences Can Recover Despite Harsh Allegations
- SAVA stock dove after a law firm made statements against the company. However, Cassava's CEO isn't just taking it lying down.
- 09/21/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences (SAVA) Investors with Losses in Excess of $250,000 to Contact Firm's Attorneys Now, Securities Class Action Pending
- San Francisco, California--(Newsfile Corp. - September 21, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and omissions concernin
- 09/21/2021
|
The Curious Case Of Cassava Sciences
- The Curious Case Of Cassava Sciences
- 09/21/2021
|
Cassava Sciences: Medical History In The Making
- Despite a sophisticated and highly profitable short attack, Cassava Sciences will commence two phase 3 trials shortly. Prior to October 1st, Cassava should release 12-month cognition data that we anticipate will be consistent with the 9-month data (ADAS-Cog11 range of -2.5 to -3.5+).
- 09/21/2021
|
Cassava Sciences, Inc. (SAVA) Stock Moves -0.52%: What You Should Know
- Cassava Sciences, Inc. (SAVA) closed at $48.26 in the latest trading session, marking a -0.52% move from the prior day.
- 09/20/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - September 20, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19727&from=5
- 09/20/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - September 20, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 09/20/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
- NEW YORK, Sept. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).
- 09/19/2021
|
SHAREHOLDER ALERT: ATVI ATIP SAVA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / September 19, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
- 09/19/2021
|
Cassava Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 19, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or options...
- 09/19/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - September 17, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more...
- 09/17/2021
|
SAVA CLASS ACTION DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - September 17, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
- 09/17/2021
|
Cassava Sciences Has Value and Is Likely To Proceed to Phase 3
- SAVA stock still has an implied upside of 67.9% to $78 per share, even if there is a 50% chance that either the shorts or longs are right. The post Cassava Sciences Has Value and Is Likely To Proceed to Phase 3 appeared first on InvestorPlace.
- 09/17/2021
|
Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - September 17, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
- 09/17/2021
|
SHAREHOLDER ALERT: ITRM ATIP SAVA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / September 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
- 09/17/2021
|
Cassava Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 16, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
- 09/16/2021
|
Rosen, Global Investor Counsel, Encourages Cassava Sciences, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
- New York, New York--(Newsfile Corp. - September 16, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.SO WHAT: If you purchased Cassava Sciences securities during the Class Period you may be entitled to compensation without payment of any out of...
- 09/16/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cassava Sciences, Inc. (SAVA)
- BENSALEM, Pa., Sept. 16, 2021 /PRNewswire/ -- Law Offices of Howard G.
- 09/16/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - September 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA: https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19629&from=5.
- 09/15/2021
|
Cassava Sciences: Is This Battleground Stock A Buy Or Sell As It Dips?
- Few stocks with a market cap above a billion dollars display as much volatility as Cassava Sciences.
- 09/15/2021
|
SAVA INVESTOR DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - September 15, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
- 09/15/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - September 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information go to:https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19615&wire=5or...
- 09/15/2021
|
SAVA LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Cassava Sciences, Inc. Shareholders
- New York, New York--(Newsfile Corp. - September 14, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=19609&from=5
- 09/14/2021
|
Class Action Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
- Radnor, Pennsylvania--(Newsfile Corp. - September 14, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") investors that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Cassava securities during the Class Period may, no...
- 09/14/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)
- New York, New York--(Newsfile Corp. - September 14, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=19596&from=5
- 09/14/2021
|
SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - September 14, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19588&wire=5
- 09/14/2021
|
Berman Tabacco Alerts Investors with Losses Over $200,000 in Cassava Sciences, Inc. (SAVA) of Approaching Lead Plaintiff Deadline
- Boston, Massachusetts--(Newsfile Corp. - September 14, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24, 2021, inclusive. ...
- 09/14/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - September 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19577&from=5
- 09/14/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cassava Sciences, Inc. (SAVA)
- LOS ANGELES, Sept. 14, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming October 26, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) securities between September 14, 2020 and August 27, 2021 , inclusive (the "Class Period").
- 09/14/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - September 14, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
- 09/14/2021
|
SAVA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Cassava Sciences, Inc. Shareholders of Class Action and Encourages Shareholders to Contact the Firm
- New York, New York--(Newsfile Corp. - September 14, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Cassava securities between February 2, 2021 and August 24, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's...
- 09/14/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - September 14, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information go to:https://www.zlk.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19565&wire=5or...
- 09/14/2021
|
Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - September 13, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
- 09/13/2021
|
SAVA CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - September 13, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
- 09/13/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
- NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).
- 09/13/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - September 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
- 09/13/2021
|
CLASS ACTION UPDATE for OTLY, ANVS and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / September 12, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
- 09/12/2021
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of QFIN, OTLY and SAVA
- NEW YORK, NY / ACCESSWIRE / September 12, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
- 09/12/2021
|
Cassava Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 12, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or options...
- 09/12/2021
|
SAVA Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Cassava Sciences, Inc. of Deadline in Securities Fraud Class Action Lawsuit
- RADNOR, Pa., Sept. 12, 2021 /PRNewswire/ -- September 12, 2021 – The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021 , inclusive (the "Class Period").
- 09/12/2021
|
What Happens When A Biotech Stock Blows Up: How Our Hedged Portfolio Method Limited The Damage With Cassava Sciences
- Screen capture via Cassava Sciences' video for their Simulfilam Alzheimer's disease treatment. When A Biotech Stock Goes The Wrong Way
- 09/11/2021
|
SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - September 10, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19505&wire=5
- 09/10/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - September 10, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19494&from=5
- 09/10/2021
|
SAVA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Cassava Sciences, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
- NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Cassava securities between February 2, 2021 and August 24, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgan
- 09/10/2021
|
Do Options Traders Know Something About Cassava Sciences (SAVA) Stock We Don't?
- Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
- 09/10/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - September 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
- 09/10/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - September 9, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 09/09/2021
|
Cassava Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 9, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
- 09/09/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - September 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
- 09/09/2021
|
Cassava Sciences to Present at H.C. Wainwright's 23rd Annual Global Investment Conference
- AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that management will present at H.C. Wainwright's 23rd Annual Global Investment Conference, a virtual event that takes place September 13-15, 2021.
- 09/09/2021
|
Cassava Sciences Stock Still Poses Risks After Absorbing Data Controversy
- Simufilam's eventual approval is still uncertain. Its fading popularity among the Reddit set is a concern as well.
- 09/09/2021
|
7 Busted Biotech Stocks Due for a Rebound
- Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on InvestorPlace.
- 09/08/2021
|
Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit
- Radnor, Pennsylvania--(Newsfile Corp. - September 8, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021, inclusive (the "Class Period").Deadline Reminder: Investors who purchased or acquired Cassava securities during the Class Period may, no...
- 09/08/2021
|
Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - September 8, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please...
- 09/08/2021
|
SAVA ALERT: Robbins Geller Rudman & Dowd LLP Announces Opportunity for Cassava Sciences, Inc. Investors with Substantial Losses to Lead the Case
- San Diego, California--(Newsfile Corp. - September 7, 2021) - Robbins Geller Rudman & Dowd LLP filed a class action lawsuit charging Cassava Sciences, Inc. (NASDAQ: SAVA) and certain of its executives with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers or acquirers of Cassava Sciences securities between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"). The Cassava Sciences class action lawsuit is pending in the...
- 09/07/2021
|
CASSAVA SCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Cassava Sciences, Inc. - SAVA
- NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 26, 2021 to file lead plaintiff applications in securities class action lawsuits against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive (the “Class Period”). These actions are pending in the United States District Co
- 09/07/2021
|
HAGENS BERMAN Reminds Cassava Sciences, Inc. (SAVA) Investors of Securities Fraud Class Action, Encourages Investors with Losses to Contact Firm's Attorneys
- San Francisco, California--(Newsfile Corp. - September 7, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and failed to discl
- 09/07/2021
|
Berman Tabacco Alerts Investors with Losses Over $200,000 of Deadline for Seeking Appointment as Lead Plaintiff in Cassava Sciences, Inc. (SAVA)
- Boston, Massachusetts--(Newsfile Corp. - September 7, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24,...
- 09/07/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - September 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between September 14, 2020 and August 27, 2021, inclusive...
- 09/07/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - September 6, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19416&from=5
- 09/06/2021
|
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
- NEW YORK, Sept. 6, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"), of the important October 26, 2021 lead plaintiff deadline.
- 09/06/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - September 6, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 09/06/2021
|
Rosen, A Top Ranked Law Firm, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SAVA
- New York, New York--(Newsfile Corp. - September 5, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no...
- 09/05/2021
|
CLASS ACTION UPDATE for JRVR, YALA and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / September 5, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
- 09/05/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
- NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).
- 09/05/2021
|
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.
- RADNOR, Pa.--(BUSINESS WIRE)---- $SAVA--Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.
- 09/04/2021
|
Better Buy: Biogen vs. Cassava Sciences
- These two biotechs are going after a significant market: Alzheimer's.
- 09/04/2021
|
Cassava Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 4, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
- 09/04/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors with Losses to Contact Firm's Attorneys Now, Securities Fraud Class Action Pending
- San Francisco, California--(Newsfile Corp. - September 3, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading sta
- 09/03/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $SAVA #SAVA--INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc.
- 09/03/2021
|
SAVA DEADLINE: Berman Tabacco Alerts Investors with Losses In Excess of $200,000 of Deadline for Seeking Appointment as Lead Plaintiff in Cassava Sciences, Inc. Class Action
- Boston, Massachusetts--(Newsfile Corp. - September 3, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24, 2021, inclusive. ...
- 09/03/2021
|
Cassava Sciences CEO says ‘enormous profit motive' behind N.Y. law firm's fraud allegations
- Cassava Sciences Inc.'s Chief Executive Remi Barbier said on Friday that recent allegations of fraud were “false and misleading” and were a result of investor interests to drive down the price of the biotechnology company's stock.
- 09/03/2021
|
Cassava CEO Goes Offensive Over Data Allegations
- Cassava Sciences Inc (NASDAQ: SAVA) has garnered attention recently after a citizen petition with the FDA suggested that the use of Alzheimer's candidate data is based on manipulation and misrepresentation. Related: Cassava Sciences Shares Sink With Alzheimer's Drug Mired In Controversy.
- 09/03/2021
|
INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors
- NEW YORK--(BUSINESS WIRE)---- $SAVA--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Western District of Texas on behalf of those who acquired Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities from September 14, 2020 through August 27, 2021, inclusive (the “Class Period”). Investors have until October 26, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Cassava is a clinical
- 09/03/2021
|
Fraud Allegations Are Unlikely to Keep Cassava Stock Down
- Cassava's unchallenged safety and cognition data will result in the FDA allowing it to conduct a Phase 3 trial. SAVA stock is a buy.
- 09/03/2021
|
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc. - SAVA
- RADNOR, Pa., Sept. 3, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (NASDAQ: SAVA) ("Cassava") on behalf of those who purchased or acquired Cassava securities betweeen September 14, 2020 and August 27, 2021 , inclusive (the "Class Period").
- 09/03/2021
|
Cassava Sciences Releases a Public Statement Regarding Recent Allegations
- AUSTIN, Texas, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today released a public statement regarding recent allegations made against the Company.
- 09/03/2021
|
Cassava Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - September 2, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) and reminds investors of the October 26, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in Cassava stock or...
- 09/02/2021
|
SAVA Lawsuit Filed: Jakubowitz Law Pursues Claims on Behalf of Cassava Sciences, Inc. Shareholders
- New York, New York--(Newsfile Corp. - September 2, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/cassava-sciences-inc-loss-submission-form/?id=19314&from=5
- 09/02/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
- New York, New York--(Newsfile Corp. - September 2, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Cassava and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 09/02/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - September 2, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19306&from=5
- 09/02/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cassava Sciences, Inc. (SAVA)
- BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Law Offices of Howard G. Smith reminds investors of the upcoming October 26, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities between September 14, 2020 and August 27, 2021, inclusive (the “Class Period”). Investors suffering losses on their Cassava investments are encouraged to contact the Law Offices of Howard G. Smith to discuss the
- 09/02/2021
|
SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - September 2, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19295&wire=5
- 09/02/2021
|
Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations
- SAVA stock is still one of the best performers this year, but the recent allegations mean shares will fall further as the story develops. The post Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations appeared first on InvestorPlace.
- 09/02/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - September 1, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more...
- 09/01/2021
|
SAVA ALERT: Berman Tabacco Announces Approaching Lead Plaintiff Deadline for Cassava Sciences, Inc. Investors with Losses in Excess of $100,000
- Boston, Massachusetts--(Newsfile Corp. - September 1, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.About the Securities Class Action FiledOn August 27, 2021, a securities class action complaint was filed in the Western District of Texas on behalf of purchasers of Cassava common stock between February 2, 2021 and August 24, 2021, inclusive...
- 09/01/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - (SAVA)
- New York, New York--(Newsfile Corp. - September 1, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA).Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/cassava-sciences-inc-loss-submission-form/?id=19247&from=5
- 09/01/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - September 1, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19239&from=5
- 09/01/2021
|
SAVA INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - September 1, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (NASDAQ: SAVA) from September 14, 2020 through August 27, 2021 (the "Class Period"). The lawsuit filed in the United...
- 09/01/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors with Losses to Contact Firm's Attorneys Now, Securities Fraud Class Period Expanded
- SAN FRANCISCO, Sept. 1, 2021 /PRNewswire/ -- Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.
- 09/01/2021
|
SAVA ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
- SAN DIEGO--(BUSINESS WIRE)-- #Cassavacase--The suit alleges defendants issued false statements concerning Cassava business and prospects, resulting in its stock trading at inflated prices.
- 08/31/2021
|
SHAREHOLDER ALERT: Robbins LLP Announces that Cassava Sciences, Inc. (SAVA) is Being Sued for Misleading Shareholders
- SAN DIEGO & AUSTIN, Texas--(BUSINESS WIRE)---- $SAVA #LawFirm--Shareholder rights law firm Robbins LLP announces that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Cassava Sciences, Inc. (NASDAQ: SAVA) securities between February 2, 2021 and August 24, 2021, for violations of the Securities Exchange Act of 1934. Cassava is a biotechnology company engaged in the development of drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simuf
- 08/31/2021
|
Cassava Sciences News: Berger Montague Investigates Securities Fraud Allegations Against Cassava Sciences Inc. (SAVA); Lead Plaintiff Deadline is October 26, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - August 31, 2021) - Berger Montague is investigating securities fraud allegations against Cassava Sciences Inc. ("Cassava" or the "Company"). The Firm is investigating these claims on behalf of investors who purchased Cassava securities (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021 (the "Class Period"). If you purchased Cassava securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests,...
- 08/31/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - August 31, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more...
- 08/31/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact Firm's Attorneys Now, Securities Fraud Class Period Expanded
- San Francisco, California--(Newsfile Corp. - August 31, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Class Period: Sept. 14, 2020 - Aug. 27, 2021Lead Plaintiff Deadline: Oct. 26, 2021Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Defendants made false and misleading statements and failed to...
- 08/31/2021
|
SAVA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cassava Sciences, Inc.
- New York, New York--(Newsfile Corp. - August 31, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19189&wire=5
- 08/31/2021
|
SAVA INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Cassava Sciences, Inc.
- NEW YORK, Aug. 31, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Cassava Sciences, Inc. ("Cassava " or the "Company") (Nasdaq: SAVA) from February 2, 2021 through August 24, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Western District of Texas alleges violations of the Securities Act of 1934.
- 08/31/2021
|
LAWSUIT FILED - Expanded Class Period: CASSAVA SCIENCES Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information
- Boston, Massachusetts--(Newsfile Corp. - August 31, 2021) - Block & Leviton announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ: SAVA) for potential securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/sava.What is this all about?On August 24, 2021, after market hours, Cassava Sciences stock dropped over...
- 08/31/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors
- LOS ANGELES--(BUSINESS WIRE)---- $SAVA #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors
- 08/31/2021
|
Short sellers betting against meme stock Cassava have made $100 million over the past month as the stock has struggled
- Short sellers have raked in millions betting against drugmaker and meme stock Cassava Sciences. But some retail investors say they're buying the dip.
- 08/31/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) securities between September 14, 2020 and August 27, 2021, inclusive (the “Class Period”). Cassava investors have until October 26, 2021 to file a lead plaintiff motion. Investors suffering losses on their Cassava investments are encouraged to contact the Law Offices of Howard G
- 08/31/2021
|
Wait to See How the Cassava Sciences Allegations Pan Out
- Allegations have been leveled against Cassava Sciences. SAVA stock has fallen by more than 50% as a result.
- 08/31/2021
|
SAVA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Cassava Sciences, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
- NEW YORK, Aug. 31, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company") NASDAQ: SAVA) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Cassava securities between February 2, 2021 and August 24, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/sava.
- 08/31/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact Firm's Attorneys Now, Securities Fraud Case Filed
- SAN FRANCISCO, Aug. 31, 2021 /PRNewswire/ -- Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now. Class Period: Feb. 2, 2021 – Aug. 24, 2021 Lead Plaintiff Deadline: Oct. 26, 2021 Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895 Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action: The complaint alleges that Cassava and senior management made false and misleading statements and failed to disclose that the quality and integrity of the scientific data supporting the company's claims of efficacy for its Alzheimer's drug (simufilam) were overstated and biased.
- 08/31/2021
|
Scrutiny Makes Cassava Sciences Stock a ‘Blood in the Street' Opportunity
- Cassava Sciences stock crashed after a lawyer sought to stop studies of the biotech's experimental Alzheimer's treatment. That just makes SAVA stock a better opportunity.
- 08/31/2021
|
SAVA DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
- SAN DIEGO, Aug. 30, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that it filed a class action lawsuit charging Cassava Sciences, Inc. (NASDAQ: SAVA) and certain of its executives with violations of the Securities Exchange Act of 1934. Purchasers of Cassava Sciences common stock between February 2, 2021 and August 24, 2021, inclusive (the "Class Period") have until October 26, 2021 to seek appointment as lead plaintiff in the Cassava Sciences class action lawsuit.
- 08/30/2021
|
SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - August 30, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and August 24, 2021Lead Plaintiff Deadline: October 26, 2021No obligation or cost to you.Learn more about your recoverable losses in SAVA:https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19158&from=5
- 08/30/2021
|
CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) in the United States District Court for the Western District of Texas on behalf of all persons and entities who purchased or otherwise acquired Cassava securities between February 2, 2021 and August 24, 2021, both dates inclusive (the “Class Period”). Invest
- 08/30/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - August 30, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 08/30/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $SAVA #SAVA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc.
- 08/30/2021
|
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline – SAVA
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 26, 2021. SO WHAT: If you purchased Cassava Sciences securities during the
- 08/30/2021
|
Cassava Sciences Is on the Ropes, so Watch for a Dip-Buy Opportunity
- Amid a regulatory tug-of-war over a proposed Alzheimer's disease treatment, SAVA stock has become a speculator's playground. The post Cassava Sciences Is on the Ropes, so Watch for a Dip-Buy Opportunity appeared first on InvestorPlace.
- 08/30/2021
|
CLASS ACTION UPDATE for LOTZ, CRMD and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
- 08/30/2021
|
Cassava Sciences And Alzheimer's Disease: Raising Doubts
- On behalf of a whistleblower or whistleblowers, the law firm of Labaton Sucharow has asked the FDA to halt Cassava Sciences' clinical trials on the basis of potential data manipulation. Perhaps the whistleblower's most serious charge is that Cassava Sciences turned to its own affiliated lab to overcome poor results reported by an independent lab.
- 08/29/2021
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SRAC, BLCT and SAVA
- NEW YORK, NY / ACCESSWIRE / August 29, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
- 08/29/2021
|
SHAREHOLDER ALERT: CRMD ATIP SAVA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / August 29, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
- 08/29/2021
|
Cassava Update
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 29, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).If you suffered losses exceeding $50,000 investing in Cassava stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information:...
- 08/29/2021
|
SAVA ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
- SAN DIEGO--(BUSINESS WIRE)-- #Cassavacase--The suit alleges defendants issued false statements concerning Cassava business and prospects, resulting in its stock trading at inflated prices.
- 08/28/2021
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Cassava investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your
- 08/27/2021
|
The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $SAVA #investors--The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
- 08/27/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Cassava Sciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 26, 2021 - SAVA
- New York, New York--(Newsfile Corp. - August 27, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Cassava Sciences, Inc. ("Cassava") (NASDAQ: SAVA) between February 2, 2021 and August 24, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Western District of Texas. To get more information...
- 08/27/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations
- San Francisco, California--(Newsfile Corp. - August 27, 2021) - Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now.Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895Cassava Sciences, Inc. (SAVA) Investigation: The investigation focuses on whether Cassava misled investors about the integrity of preliminary analysis of a small clinical trial of the company's Alzheimer's drug, simufilam. On July 29, 2021 Cassava...
- 08/27/2021
|
Cassava Sciences punches back, after Qaunterix took a swing by saying it didn't interpret or prepare the disputed trial data
- Quanterix Corp. took a swing at Cassava Sciences Inc. Friday, but then Cassava hit back, stressing that Quanterix was contracted to perform sample testing of the trial data that have been disputed.
- 08/27/2021
|
SAVA: Berman Tabacco Alerts Investors with Losses of $100,000 from Investments in Cassava Sciences, Inc. of Deadline to Apply to Serve as Lead Plaintiff
- Boston, Massachusetts--(Newsfile Corp. - August 27, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. If you sustained losses in excess of $100,000 from your transactions in Cassava securities during the Class Period and are interested in learning more about serving as Lead Plaintiff, please provide your information here: Shareholder Contact |...
- 08/27/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Law Offices of Howard G. Smith continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company's possible violations of federal securities laws. On August 24, 2021, after the market closed, it was revealed that a Citizen Petition was filed with the United States Food and Drug Administration (“FDA”) requesting that the FDA halt two ongoing trials of Cassava's proprietary drug Simufilam. T
- 08/27/2021
|
SAVA NOTICE: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
- SAN DIEGO, Aug. 27, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP today announced that it filed a class action lawsuit charging Cassava Sciences, Inc. (NASDAQ: SAVA) and certain of its executives with violations of the Securities Exchange Act of 1934 and seeking to represent purchasers of Cassava Sciences common stock between February 2, 2021 and August 24, 2021, inclusive (the "Class Period"). The Cassava Sciences class action lawsuit was commenced on August 27, 2021 in the Western District of Texas and is captioned Brazeau v.
- 08/27/2021
|
Why the Cassava Sciences Bears Are Wrong
- The stock's been a wild ride for investors all year, and it's dropped more than 50% in two days. What's going on, and why am I bullish?
- 08/27/2021
|
Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer's Patients
- AUSTIN, Texas, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer's disease. For this study, Cassava Sciences contracted with Quanterix Corp., a highly regarded, independent laboratory, to perform sample testing on blinded samples.
- 08/27/2021
|
Ongoing Investigation Alert: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES, Aug. 27, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ: SAVA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 08/27/2021
|
Why Cassava Sciences Is Plunging Again Today
- More red flags are emerging for this troubled Alzheimer's biotech company.
- 08/27/2021
|
Why Cassava Sciences Stock Investors Are Pulling Back
- The neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ: SAVA) has now lost half of its market capitalization. What Happened: Cassava shares plunged Wednesday in reaction to a citizen petition calling for halting clinical studies of its lead drug candidate simufilam due to alleged data manipulation and misrepresentation.
- 08/27/2021
|
Which Biotech Stock Will Shock the Market in 2022?
- Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?
- 08/27/2021
|
Cassava's stock tumbles again, after Quanterix said it 'did not' prepare data charts presented by Cassava, that are under dispute
- Quanterix Corp. QTRX, -9.21% said that while it was previously engaged by Cassava Sciences Inc. SAVA, -12.38% to perform sample testing, the digitized biomarker analysis company said it, or its employees, "did not interpret the test results or prepare the data charts" presented by Cassava to the Alzheimer's Association International Conference (AAIC) in July, or otherwise. Earlier this week, in Cassava's response to a request the Food and Drug Administration halt clinical studies of Cassava's Alzheimer's treatment because of concerns over the accuracy and integrity of presented biomarker data, Cassava had said that data from Alzheimer's patients were generated by Quanterix.
- 08/27/2021
|
Specious Claims And Spurious Accusations Are All The Bears Can Muster Against Cassava Sciences
- The petition filed against Cassava Sciences is so misleading and wrong-headed it seems an intentional act of FUD and not a serious request.
- 08/27/2021
|
After A 30% Fall Cassava Stock Is Likely To See Lower Levels
- The stock price of Cassava Sciences, a clinical stage biotechnology company focused on treatment for Alzheimer's disease, has seen a large 31% decline in a single trading session on Aug 25. SAVA stock has had a volatile ride over the last year or so, and despite yesterday's fall, the stock is.
- 08/27/2021
|
CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences on Behalf of Cassava Sciences Stockholders and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava Sciences” or the “Company”) (NASDAQ: SAVA) on behalf of Cassava Sciences stockholders. Our investigation concerns whether Cassava Sciences has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 24, 2021, after the market
- 08/26/2021
|
Cassava Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 26, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).If you suffered losses exceeding $50,000 investing in Cassava stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information:...
- 08/26/2021
|
SAVA Alert: Berman Tabacco Investigates Cassava Sciences, Inc. for Potential Securities Claims in Connection with FDA Citizen Petition
- Boston, Massachusetts--(Newsfile Corp. - August 26, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.On August 25, 2021, Bloomberg reported that shares of Cassava were down 31% "after a lawyer sought to stop studies of the biotech company's experimental treatment for Alzheimer's disease." According to Bloomberg, "a citizen petition from a former Securities...
- 08/26/2021
|
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $SAVA #SAVA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc.
- 08/26/2021
|
Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor
- Cassava has received the go-ahead from the FDA to initiate two pivotal trials of its Alzheimer's therapy Simufilam. One week ago, however, a citizen's petition filed with the FDA insisted that data from earlier studies of Simufilam had been manipulated in various ways.
- 08/26/2021
|
Why Traders Shouldn't Bargain Hunt in Cassava Stock
- Wall Street is notorious for its overreactions, but when it comes to SAVA stock's cratering, investors consider other historical precedents. The post Why Traders Shouldn't Bargain Hunt in Cassava Stock appeared first on InvestorPlace.
- 08/26/2021
|
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Inquire About Class Action Investigation – SAVA
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) resulting from allegations that Cassava Sciences may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cassava Sciences securities you may be entitled to compensation without payment of any out of pocket fees or costs through a conting
- 08/26/2021
|
As Allegations Swirl, Can Investors Still Count on Cassava Sciences Stock?
- This once-promising biotech is now struggling to stay afloat.
- 08/26/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. (SAVA) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations
- SAN FRANCISCO, Aug. 26, 2021 /PRNewswire/ -- Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/SAVA Contact An Attorney Now: SAVA@hbsslaw.com 844-916-0895 Cassava Sciences, Inc. (SAVA) Investigation: The investigation focuses on whether Cassava misled investors about the integrity of preliminary analysis of a small clinical trial of the company's Alzheimer's drug, simufilam.
- 08/26/2021
|
Biotech Stock Tries to Recover as Alzheimer's Drug Draws Questions
- Cassava Sciences Inc (NASDAQ:SAVA) is up 4.1% at $84.16 this morning, in an attempt to bounce back from yesterday's news that its Alzheimer's drug was facing scrutiny.
- 08/26/2021
|
Better Biotech Stock: Cassava Sciences vs. Annovis Bio
- It boils down to which company's clinical trial results look better for treating Alzheimer's at the moment.
- 08/26/2021
|
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $SAVA #SAVA--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc.
- 08/25/2021
|
Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company and its officers' possible violations of the federal securities laws. If you suffered a loss on your Cassava investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit
- 08/25/2021
|
Cassava Investor Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 25, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA).If you suffered losses exceeding $50,000 investing in Cassava stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information:...
- 08/25/2021
|
The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $SAVA #investors--The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
- 08/25/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Law Offices of Howard G. Smith continues its investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company and its officers' possible violations of federal securities laws. On August 24, 2021, after the market closed, it was revealed that a Citizen Petition was filed with the United States Food and Drug Administration (“FDA”) requesting that the FDA halt two ongoing trials of Cassava's proprietary d
- 08/25/2021
|
SAVA Stock: Cassava Sciences Sinks Despite Countering Trial Data Allegations
- Today, investors in Cassava Sciences and SAVA stock are seeing a lot of red, as investors digest a statement of concern filed yesterday. The post SAVA Stock: Cassava Sciences Sinks Despite Countering Trial Data Allegations appeared first on InvestorPlace.
- 08/25/2021
|
SHAREHOLDER ALERT: Investigation of Cassava Sciences, Inc. Announced by Holzer & Holzer, LLC
- Atlanta, Georgia--(Newsfile Corp. - August 25, 2021) - Holzer & Holzer, LLC is investigating whether Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA) complied with federal securities laws. On August 24, 2021, it was revealed that a Citizen Petition had been filed with the FDA, questioning the quality and integrity of the Company's research and data, suggesting the data had been manipulated. The Petition further sought a halt to Cassava's current clinical...
- 08/25/2021
|
2 Little-Known Nasdaq Stocks Making Big Moves Wednesday
- Don't let these companies fly under your radar.
- 08/25/2021
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $SAVA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Cassava investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securitie
- 08/25/2021
|
Shareholder Alert: Berman Tabacco Announces Investigation of Cassava Sciences, Inc. (SAVA) for Potential Securities Law Violations
- Boston, Massachusetts--(Newsfile Corp. - August 25, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company. On August 25, 2021, Bloomberg reported that shares of Cassava were down over 20% in pre-market trading "after a lawyer asked the FDA to halt the company's clinical trials of an experimental drug, citing concerns about the...
- 08/25/2021
|
7 Bargain Stocks to Buy Under $5 With the Right Catalysts
- The risk in these inexpensive bargain stocks is offset by their upside for investors looking for a little more spice in their portfolio. The post 7 Bargain Stocks to Buy Under $5 With the Right Catalysts appeared first on InvestorPlace.
- 08/25/2021
|
Here's why Cassava Sciences stock tanked 30% Wednesday morning
- Cassava Sciences Inc (NASDAQ: SAVA) reached an SPA (Special Protocol Assessment) agreement with the U.S. FDA on Tuesday morning for the phase 3 trial of its Alzheimer's treatment, Simufilam. Shares of the company, however, tanked about 30% this morning on a statement of concern that raised a question on the integrity of western blot analyses […] The post Here's why Cassava Sciences stock tanked 30% Wednesday morning appeared first on Invezz.
- 08/25/2021
|
Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near
- SAVA stock is up as the company announced the FDA has agreed on study protocols for Phase 3 clinical trials of Simufilam. The post Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near appeared first on InvestorPlace.
- 08/25/2021
|
Cassava Sciences Shares Sink With Alzheimer's Drug Mired In Controversy
- Neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ: SAVA) saw both sides of the world Tuesday. The stock rallied to close higher by 2% after it announced an agreement with the Food and Drug Administration regarding two late-stage studies of its lead drug candidate simufilam in Alzheimer's disease.
- 08/25/2021
|
Why Cassava Sciences' Stock Is Getting Hammered Today
- Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading lower on negative claims that were posted online yesterday after market hours. The company issued a response to the claims today, saying they believe the claims regarding scientific integrity are false and misleading.
- 08/25/2021
|
SAVA Stock: Over 20% Decrease Pre-Market Explanation
- The stock price of Cassava Sciences Inc (NASDAQ: SAVA) fell by over 20% pre-market. This is why it happened.
- 08/25/2021
|
Cassava Sciences stock tumbles, and company responds to allegations disputing trial data
- Cassava Sciences Inc. SAVA, +1.92% responded Wednesday to allegations posted overnight regarding the "accuracy and integrity" of trial data for its treatment of Alzheimer's disease, saying it believed the claims are "false and misleading." Cassava's stock had rallied 1.9% on Tuesday, and 16.4% over the past three days, with the company saying early Tuesday that it reached agreement with the Food and Drug Administration under a Special Protocol Assessment (SPA) for its Phase 3 studies of oral simufilam for the treatment of Alzheimer's patients.
- 08/25/2021
|
Cassava Sciences Responds to Allegations
- AUSTIN, Texas, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today issued a response to claims that were posted on-line yesterday after market hours. Cassava Sciences believes the claims made in this post regarding scientific integrity are false and misleading. The Company stands behind its science, its scientists and its scientific collaborators, and is responding to ensure the facts are known and respected.
- 08/25/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $SAVA #ClassAction--Law Offices of Howard G. Smith Announces Investigation of Cassava Sciences, Inc. (SAVA)
- 08/25/2021
|
Cassava Sciences Has an Admirable Goal at Too High a Price
- It would be great if Cassava Sciences' treatment for Alzheimer's disease worked, but should you pay the high price for SAVA stock? No. The post Cassava Sciences Has an Admirable Goal at Too High a Price appeared first on InvestorPlace.
- 08/24/2021
|
5 Penny Stocks That Turned $2,500 Into Over $29,000 In 2021 So Far
- Hot Penny Stocks That Scored Huge For Traders In 2021 The post 5 Penny Stocks That Turned $2,500 Into Over $29,000 In 2021 So Far appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/24/2021
|
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer's Disease
- Phase 3 Study Initiation Still Expected Fall 2021 Phase 3 Study Initiation Still Expected Fall 2021
- 08/24/2021
|
Soaring Cassava Sciences Stock Shows Unfettered Promise for Growth
- With more than 6 million people in the U.S. suffering from Alzheimer's disease, SAVA stock has enormous potential for future profits. The post Soaring Cassava Sciences Stock Shows Unfettered Promise for Growth appeared first on InvestorPlace.
- 08/20/2021
|
Cassava Sciences Stock Has Had an Epic Run, but Getting in Now Is a Serious Risk
- Given it's at risk of a severe pullback if it stumbles going forward? If you own, take some risk off the table, by partially paring down your position.
- 08/19/2021
|
These Are the Top Reasons You Should Load Up on Cassava Sciences Stock
- At the moment, there's no cure for Alzheimer's, but Cassava Sciences is working to wipe it out for good making SAVA stock a buy here. The post These Are the Top Reasons You Should Load Up on Cassava Sciences Stock appeared first on InvestorPlace.
- 08/18/2021
|
With This Exciting Alzheimer's Treatment, Cassava Sciences Stock Has Legs
- Incredible Alzheimer's data suggests that Cassava has the right approach to tackling the disease powering SAVA stock The post With This Exciting Alzheimer's Treatment, Cassava Sciences Stock Has Legs appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America's #1 EV Stock Still Flying Under the Radar
- 08/16/2021
|
Cassaca Sciences Stock Is a Buy on the Strength of a Promising Alzheimer's Drug
- Skeptics are wrong about Cassava's Alzheimer's drug, as the drug's data is superb. Long-term investors should buy SAVA stock.
- 08/16/2021
|
Why Might Cassava Succeed With Its Alzheimer's Drug, When So Many Have Failed?
- Alzheimer's research has been hampered by apparently mistaken ideas about what causes the disease. Cassava has a new theory about what's responsible -- and its drug is showing positive results.
- 08/14/2021
|
Analyzing the Potential Risks of Cassava Sciences
- Cassava Sciences has a promising drug candidate for Alzheimer's. However, SAVA stock may be overpriced based on the limited data so far.
- 08/13/2021
|
Why Is Cassava Sciences' Stock So Volatile?
- The stock is up 1,700% year to date.
- 08/12/2021
|
Cassava Sciences vs. Biogen
- Who will emerge victorious in the race to help Alzheimer's patients?
- 08/12/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
- NEW YORK, Aug. 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S.
- 08/11/2021
|
Here's What Investors Should Know About Cassava's Alzheimer's Drug Candidate
- Cassava believes that a mutating protein, Filamin A, is a major culprit behind Alzheimer's disease. The company's drug, simufilam, aims to fix this mutation and restore its proper form and function.
- 08/11/2021
|
Bring a Neck Brace When Trading Cassava Sciences
- Cassava is still pre-revenue but SAVA stock has a flock of strong fans. They bought the dip with gumption, which suggests long-term success.
- 08/11/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
- New York, New York--(Newsfile Corp. - August 9, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Cassava and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 08/09/2021
|
Why Shares of Cassava Sciences Fell 18.6% in July
- The stock lost $75 a share in two days at the end of the month.
- 08/09/2021
|
What to Do After Cassava Sciences Dropped Off a Cliff
- Cassava Sciences posted positive clinical data but triggered a sell on the news event, as SAVA stock short sellers welcomed the drop. The post What to Do After Cassava Sciences Dropped Off a Cliff appeared first on InvestorPlace.
- 08/09/2021
|
Cassava Sciences May Be Revolutionary in the Alzheimer's Fight
- SAVA stock is truly worth paying attention to from here forward as data suggests Cassava Sciences may have solved a big mystery. The post Cassava Sciences May Be Revolutionary in the Alzheimer's Fight appeared first on InvestorPlace.
- 08/05/2021
|
Are Penny Stocks Worth It? 5 That Deserve Your Attention Now
- Have penny stocks presented some of the biggest opportunities in the stock market? The post Are Penny Stocks Worth It?
- 08/05/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
- NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA). Such investors are advised to contact Robert S.
- 08/03/2021
|
Detours In The Golden Age Of Alzheimer's Drug Stock Investments
- Biogen's Aduhelm performed no better than placebo in non-ApoE4 carriers and only slightly slowed down the progression of Alzheimer's disease in ApoE4 carriers.
- 08/03/2021
|
SAVA Stock Price Increases Over 17% Intraday: Why It Happened
- The stock price of Cassava Sciences Inc (NASDAQ: SAVA) increased by over 17% during intraday trading. This is why it happened.
- 08/03/2021
|
Cassava Sciences Stock Has Been Hammered For No Good Reason and Is Likely To Rebound
- Cassava Sciences stock has been hammered for no good reason and is likely to rebound. AVA stock is still worth over $900 especially given the recent positive 9-month results of its Alzheimer's drug Simufilam.
- 08/03/2021
|
Why Former NYSE Trader David Green Bought NVIDIA, Tesla, and Cassava Sciences On Tuesday
- Veteran trader David Green was back live trading on Benzinga Tuesday morning, and the long-time trader made some moves. Green pointed out the strength of NVIDIA Corporation (NASDAQ:NVDA) Tuesday morning.
- 08/03/2021
|
Cassava Sciences Reports Second Quarter 2021 Financial Results
- - Conference Call Today at 9 a.m. ET - - Conference Call Today at 9 a.m. ET -
- 08/03/2021
|
5 Ultra-Popular Stocks to Avoid Like the Plague in August
- These stocks look to be more trouble than they're worth.
- 08/03/2021
|
Cassava Sciences Announces Conference Call for Second Quarter Financial Results
- - Call-in on Tuesday, August 3rd at 9 a.m. ET - - Call-in on Tuesday, August 3rd at 9 a.m. ET -
- 08/02/2021
|
Cassava Sciences' Simufilam Is The First Alzheimer's Drug To Work At 9 Months, And The Benefit Is Growing
- Simufilam is the first AD drug to show a cognitive improvement at 9 months, with a gaudy 18% mean improvement from baseline. Simufilam also showed a growing behavioral benefit.
- 07/30/2021
|
SAVA Stock Fell 23.61%: Details You Should Know
- The stock price of Cassava Sciences Inc (NASDAQ: SAVA) fell by over 25% during intraday trading. These are some details you should know.
- 07/29/2021
|
Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data
- As Cassava Sciences made progress in treating Alzheimer's, SAVA stock is on a powerful path to significantly higher prices. The post Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data appeared first on InvestorPlace.
- 07/29/2021
|
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
- A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.
- 07/29/2021
|
Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?
- This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease.
- 07/29/2021
|
Cassava Sciences: Critical Alzheimer's Data Due Thursday Offers Upside Potential
- Cassava Sciences shares are +3,300% in the past year, but the upside could continue until the $4.5bn market cap biotech achieves a >$50bn valuation.
- 07/27/2021
|
Cassava Sciences Stock Could Be Worth $900 After Its Upcoming Alzheimer's Results
- Cassava Sciences stock could jump with its upcoming Alzheimer's results. SAVA stock options show the lofty expectations investors have.
- 07/23/2021
|
An Unforgettable Week For Alzheimer's Treatment Stocks: Two Of Our Recent Top Names Spike On News Of Potentially Promising Treatments
- Screen capture via IGC's healthcare subsidiary Hyalolex. "Drops of Clarity" is their just-patented Alzheimer's treatment.
- 07/23/2021
|
Cassava Sciences Stock Soars In Anticipation Of Alzheimer's Data: A Technical Analysis
- On Thursday, Cassava Sciences, Inc (NASDAQ: SAVA) smashed through a resistance level at $117.54, made 21 years ago between its initial public offering date of June 14, 2000 and December of that year. On Wednesday, the biopharmaceutical company announced it will present new clinical-trial data from a Phase 2 trial of its drug simufilam at the Alzheimer's Association International Conference (AAIC) on July 29.
- 07/22/2021
|
Cassava Sciences stock price forecast for Q3 after shares rally 27%
- Meme stock Cassava Sciences Inc. (NASDAQ:SAVA) shares surged more than 27% on Wednesday after revealing plans to present data on its Alzheimer's drug, Simufilam, on 29th July. Cassava will read out its interim analysis on a 9-month treatment with Simulflam at the 2021 Alzheimer's Association International Conference (AAIC) in Denver.
- 07/21/2021
|
Here's Why Cassava Sciences Is Surging Today
- Investors are excited about upcoming presentations scheduled for the annual Alzheimer's Association International Conference.
- 07/21/2021
|
SAVA Stock: Two Dates Cassava Investors Need to Mark on Their Calendars
- SAVA stock is flying upward today as investors clamor to hear information around two new products. Investors should save two upcoming dates.
- 07/21/2021
|
SAVA Stock Increases Over 33% Intraday: Why It Happened
- The stock price of Cassava Sciences Inc (Nasdaq: SAVA) increased by over 33% during intraday trading. This is why it happened.
- 07/21/2021
|
3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021
- Are biotech penny stocks on your watch list in 2021? The post 3 Biotech Penny Stocks To Watch Seeing Explosive Gains In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/21/2021
|
Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer's Association International Conference
- - On Monday, July 26 th , New Clinical Data for SavaDx to be Shared in a Poster Presentation -
- 07/21/2021
|
Here's Why Cassava Sciences Is Up 1,152% in the First Half of 2021
- This small-cap biotech has shot up in value as the company's Alzheimer's drug makes it way through clinical trials.
- 07/20/2021
|
Why Is Cassava Sciences Stock Soaring in 2021?
- The stock market is excited by the clinical trial results for its Alzheimer's drug.
- 07/20/2021
|
Cassava Sciences Is On The Brink Of Making Medical History
- Cassava is dramatically undervalued.
- 07/20/2021
|
Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?
- Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.
- 07/16/2021
|
Why Cassava Sciences Stock Moved Higher Monday
- The biotech stock bounced back big Monday after tumbling on Friday.
- 07/12/2021
|
7 Top-Rated Pharmaceutical Companies to Invest In for July
- Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In for July appeared first on InvestorPlace.
- 07/09/2021
|
Anavex: A Catalyst-Rich Year
- Anavex: A Catalyst-Rich Year
- 07/05/2021
|
This Biotech Stock Is Beating GameStop
- Now the question is whether the gains are here to stay.
- 07/01/2021
|
Is It Too Late to Buy Cassava Sciences Stock?
- Just because the stock has had a massive run doesn't mean its biggest gains are behind it.
- 06/26/2021
|
Could Cassava Sciences Be a Millionaire-Maker Stock?
- Can this biotech underdog develop an Alzheimer's drug investors can count on?
- 06/24/2021
|
Cassava (SAVA) Stock Up on Alzheimer's Candidate Update
- Cassava Sciences' (SAVA) completes enrollment in its open-label study on simufilam. It plans to begin two pivotal phase III studies on simufilam in the second half of 2021.
- 06/22/2021
|
Cassava Sciences (SAVA) is Overbought: Is A Drop Coming?
- Cassava Sciences (SAVA) has moved higher as of late, but there could definitely be trouble on the horizon for this company
- 06/22/2021
|
Why Cassava Sciences Stock Soared Today
- Investors applauded the company's update on its clinical programs.
- 06/21/2021
|
Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer's Disease
- Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer's Disease Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer's Disease
- 06/21/2021
|
Why Cassava Sciences Shares Are Moving Today
- Cassava Sciences Inc (NASDAQ:SAVA) shares are trading higher by 11.2% at $88.50 after the company highlighted clinical development progress and provided guidance on upcoming data releases for simufilam, the company's lead drug candidate to treat Alzheimer's disease. Cassava Sciences is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease.
- 06/21/2021
|
Cassava Sciences Stock Gains After Outlining Clinical Development Progress For Lead Alzheimer's Candidate
- Cassava Sciences Inc (NASDAQ: SAVA) has announced a mid-year update highlighting clinical development progress and providing guidance on upcoming data releases for simufilam and SavaDx. Simufilam is Cassava's lead drug candidate to treat Alzheimer's disease; SavaDx is an investigational diagnostic candidate to detect Alzheimer's with a simple blood test.
- 06/21/2021
|
Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference
- AUSTIN, Texas, June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference, a virtual event taking place on June 21-23, 2021.
- 06/17/2021
|
These 2 Biotech Stocks Are Up 1,000% This Year
- New approaches to treating Alzheimer's could mean even bigger gains in the future.
- 06/16/2021
|
Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors
- - Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals –
- 06/14/2021
|
Why Cassava Sciences Was Up 15% in May
- Thanks to key funding, its Alzheimer's drug is on track even after Biogen's historic approval.
- 06/07/2021
|
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
- Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
- 06/02/2021
|
Are Options Traders Betting on a Big Move in Cassava Sciences (SAVA) Stock?
- Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
- 05/25/2021
|
Annovis' Alzheimer's Drug Is Interesting, Cassava's Looks Better
- Annovis Bio tripled Friday after reporting exciting Alzheimer's data. Its drug posiphen is not clearing plaques or flooding receptors, but inhibits amyloid-β precursor protein from translating toxic Aβ.
- 05/24/2021
|
Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer's Disease
- - Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time -
- 05/24/2021
|
Long-Term Small Molecule Studies Bode Well For Cassava Sciences' Alzheimer's Data
- The only effective Alzheimer's treatment on the market is aricept, but its effect falls off after six months because it simply floods receptors.
- 05/18/2021
|
Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development
- Caladrius Biosciences Inc (NASDAQ: CLBS) has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority. The Program enables qualifying companies to sell a percentage of their New Jersey net operating losses and research and development tax credits to unrelated qualifying corporations.
- 05/12/2021
|
Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health
- - Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam - - Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam -
- 05/12/2021
|
Buying Cassava Sciences Ahead Of July Data
- The stock is off >70% from February high after going up 3x after the interim Alzheimer's data. Targeting $70 by the second interim data release in July (70% upside potential).
- 05/10/2021
|
Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer's disease
- - Randomized, Controlled Study is Designed to Evaluate Cognition in Patients Who Continue Versus Discontinue Simufilam Over Six Months –
- 05/10/2021
|
Cassava Sciences Invited to Participate in B. Riley Securities' Neuroscience Conference
- Fireside Chat on Wednesday, April 28th at 2:30PM Eastern Fireside Chat on Wednesday, April 28th at 2:30PM Eastern
- 04/27/2021
|
